FOXO family and neurodegenerative diseases: Mechanisms of action and therapeutic potential Authors: Zhengxiang Lv, Xiaodong Liu, Zhiwei Zhou, Qin Huang, Haijun Liu, Zucai Xu, Ping Xu Published: 2026 ABSTRACT AbstractNeurodegenerative diseases (NDDs) lack effective disease-modifying therapies. The FOXO transcription factors serve as integrative hubs of cellular stress responses, operating through cell-autonomous homeostasis, intercellular coordination, intracellular quality control, and cell fate decisions four hierarchical tiers. This review systematically examines isoform-specific functions: FOXO1 governs metabolic reprogramming and mitochondrial biogenesis; FOXO3 acts as the principal oxidative stress sensor with context-dependent neuroprotective or pro-apoptotic outputs; FOXO4 regulates cellular senescence; and FOXO6 maintains synaptic metabolic support. These functions vary across cell types and disease stages, with post-translational modifications determining functional transitions. FOXO proteins participate in complex interactions with disease-specific pathological proteins, either promoting clearance and repair or exacerbating neurodegeneration depending on stress intensity and chronicity. Therapeutic strategies targeting FOXO remain in preclinical and early clinical stages. Key challenges include disease stage-dependent dosing, cell-type-specific delivery, blood-brain barrier penetration, and metabolic side effects. Future directions emphasize biomarker-guided patient stratification and precision interventions aligned with the spatiotemporal dynamics of FOXO signaling. Unlike prior reviews focusing on single pathways or diseases, this work integrates isoform-specific, stage-dependent, and cell-type-resolved FOXO functions into a unifying hierarchical framework.Keywords: FOXO family proteins, Neurodegenerative diseases, Molecular mechanisms, Oxidative stress, Targeted therapy, Epigenetic regulation Introduction Neurodegenerative diseases (NDDs) constitute a heterogeneous group of disorders characterized by progressive neuronal loss and dysfunction, encompassing Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), multiple sclerosis (MS), and frontotemporal dementia (FTD). As global populations age, the incidence of these conditions has risen dramatically, posing an escalating public health burden worldwide [1,2]. Despite extensive research efforts, as described in Fig. 1, disease-modifying therapies capable of halting or reversing pathological progression remain largely elusive, leaving a critical unmet medical need. Timeline of FOXO transcription factors in neurodegenerative diseases (1988211;2024). This timeline highlights major discoveries linking FOXO family proteins to neurodegeneration across four decades. Key milestones include: (i) Discovery era (1988–1993): initial FOXO gene identification in Drosophila (Ingham, 1988) and the seminal finding that FOXO/DAF-16 regulates lifespan (Kenyon, 1993); (ii) Neuroprotective mechanisms era (2003–2004): FOXO3-mediated DNA repair (Tran, 2003), autophagy activation (Ravikumar, 2003), and the SIRT1-FOXO3 deacetylation axis (Brunet, 2004); (iii) Disease-specific roles era (2014–2015): FOXO3 regulation of α-synuclein aggregation in Parkinson's disease (Pino, 2014) and TDP-43 proteinopathy in ALS/FTD (Zhang, 2015); and (iv) Therapeutic translation era (2021–2024): FOXO1-targeted interventions for Huntington's disease (Furtado, 2021) and FOXO6-mediated motor neuron survival (Thonhoff, 2024). Color coding: blue bars indicate fundamental discoveries; green bars denote neuroprotective mechanism elucidation; orange bars mark disease-specific pathological findings; purple bars signify therapeutic advances. The width of each bar corresponds to the duration of research impact. Abbreviations: FOXO, Forkhead box O; SIRT1, Sirtuin 1; TDP-43, TAR DNA-binding protein 43. The FOXO (Forkhead box O) family of transcription factors, discovered in 1988 and formally named in 2000 [3,4] (Fig. 1), has garnered considerable scientific interest as key transcriptional regulators and emerged as a central regulatory hub in cellular stress responses. This evolutionarily conserved family comprises four principal mammalian isoforms: FOXO1, FOXO3, FOXO4, and FOXO6 [[5], [6], [7]]. FOXO proteins orchestrate the transcriptional regulation of over 200 target genes governing metabolism, redox homeostasis, inflammatory responses, and programmed cell death [8,9]. Sophisticated PTMs confer functional plasticity to FOXO proteins. These PTMs act as a molecular code. They integrate diverse environmental cues into adaptive transcriptional programs [10,11]. This multilayered architecture establishes FOXO proteins as central signaling hubs. They integrate extracellular cues and convert them into adaptive transcriptional programs. In the nervous system, FOXO-mediated gene networks constitute essential components of endogenous neuroprotection, coordinating defenses against mitochondrial oxidative stress species (O2▪-, H2O2). Physiological levels of these ROS activate FOXO nuclear translocation and SIRT1-dependent deacetylation, upregulating antioxidant enzymes (SOD2, CAT) and autophagy regulators to maintain redox homeostasis under physiological and pathological conditions [12,13]. Compelling evidence from human genetics, neuropathological studies, and experimental models has established intimate connections between FOXO dysregulation and NDD pathogenesis. In AD, FOXO proteins modulate amyloid-beta (Aβ) metabolism and tau phosphorylation dynamics [14]; in PD, their antioxidant and anti-apoptotic functions are critical for dopaminergic neuron survival [15,16]; in ALS, aberrant FOXO1 activation drives skeletal muscle intrinsic dysfunction preceding motor neuron degeneration [17,18]; and in HD, FOXO-mediated proteasomal and autophagic pathways facilitate clearance of mutant huntingtin (mHTT) aggregates [[19], [20], [21]]. These isoform-specific and context-dependent functions underscore the therapeutic potential of precisely targeting FOXO signaling nodes. Given these unresolved questions, this review integrates isoform-specific, stage-dependent, and cell-type-resolved evidence to map FOXO signaling in NDDs. We introduce a four-tier hierarchical framework that maps FOXO functionality across progressive disease stages, culminating in a precision intervention matrix aligned with stage-resolved clinical biomarkers. Search strategy A systematic literature search was conducted across multiple databases from January 2004 to September 2025 to capture mechanistic and translational evidence on FOXO family proteins in neurodegenerative diseases (NDDs). For mechanistic studies, we searched PubMed, Web of Science, and CNKI using combined MeSH terms and keywords: ("Forkhead box O" OR "FOXO1" OR "FOXO3" OR "FOXO4" OR "FOXO6") AND disease-specific terms (e.g., "Alzheimer's disease", "Parkinson's disease", "amyotrophic lateral sclerosis", "Huntington's disease", "multiple sclerosis", "frontotemporal dementia"). Inclusion criteria encompassed peer-reviewed original research, clinical studies, and systematic reviews with quantitative data on FOXO-related outcomes in human subjects, human-derived tissues, or validated animal models. Studies were excluded for inadequate sample size, lack of appropriate controls, or incomplete FOXO activity assessment. To comprehensively capture translational and clinical development data (Section 7), we additionally queried: ClinicalTrials.gov (https://clinicaltrials.gov), U.S. FDA Novel Drug Approvals database (https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals), and NIH RePORTER (https://reporter.nih.gov). Screening was managed using EndNote, with two independent reviewers assessing titles/abstracts. Disagreements were resolved by consensus with a senior investigator. After full-text review of ∼430 articles, approximately 396 original research articles, supplemented by relevant reviews, clinical trial records, and regulatory documents, formed the evidentiary basis for this synthesis. Structure and biological properties of FOXO family members The FOXO family comprises four evolutionarily conserved isoforms, including FOXO1, FOXO3, FOXO4, and FOXO6, which share a structurally invariant forkhead domain (FHD) of approximately 110 amino acids. This domain adopts a winged-helix conformation, characterized by a helix-turn-helix motif and two flanking β-strands, and binds the consensus DNA sequence 5'-G(T/A)AAA(C/T)-3' with nanomolar (nM) affinity [22]. This specific binding underlies the transcriptional regulation of over 200 target genes governing metabolism, redox homeostasis, inflammatory responses, and programmed cell death [8,9]. Crystallographic analyses reveal that the FHD docks into the major groove via α-helix H3, while the W1 loop confers sequence specificity critical for distinguishing promoter elements of antioxidant genes, autophagy regulators, and apoptotic effectors. The C-terminal transcriptional activation domain, by contrast, exhibits isoform-specific variability, providing a scaffold for the recruitment of chromatin-modifying enzymes and integrating post-translational sig NRF2 pathway to induce heme oxygenase-1 pro-degenerative states (summarized in Table 1). Table 1Post-translational modifications (PTMs) of FOXO proteins: molecular switches determining activity and function.Table 1ModificationIsoformEnzymeTarget ResidueFunctional OutcomeNDDs RelevancePhosphorylationFOXO1/3/4AKT/PKBThr32, Ser253, Ser315Cytoplasmic retentionAKT ↓ → FOXO nuclear ↑↑ → aberrant gene transcription (AD) [8,9,23]FOXO1/3JNK/p38 MAPKSer207, Ser329Nuclear retentionElevated O2▪-/H2O2→ JNK-FOXO3 ↑ → dopaminergic neuron survival (PD) [10,24]FOXO3AMPKSer574Nuclear retentionEnergy crisis → mitochondrial dysfunction (PD, HD) [25,26]AcetylationFOXO3CBP/p300Lys242/245DNA-binding ↓Mutant Htt → CBP/p300 HAT ↓ → FOXO3-BDNF ↓ (HD) [[27], [28], [29]]FOXO3SIRT1/SIRT3Lys242/245Chromatin occupancy ↑Aging/NAD+ decline → SIRT1 ↓ → FOXO3 hyperacetylation → apoptosis (ALS, AD) [30,31]UbiquitinationFOXO1/3SKP2, MDM2—Proteasomal degradationDysregulation → FOXO ↑↑ (NDDs understudied) [[6], [7], [8]]MethylationFOXO3DNMT1—NLRP3 promoter methylationNeuroinflammation suppression (AD, MS) [32,33]O-GlcNAcylationFOXO1OGT—Nuclear localization ↑Glucose sensing → metabolic adaptation → OS resistance (mediated by O2▪-/H2O2) (AD) [[34], [35], [36]]NOTE: ↑, Upregulation/Increase; ↓, Downregulation/Decrease; O2▪- is primarily generated at mitochondrial electron transport chain Complex I and III; H2O2 is produced by dismutation of O2▪- by SOD2 or directly by monoamine oxidase during dopamine catabolism. Abbreviations: HAT, histone acetyltransferase; NDDs, neurodegenerative diseases; OGT, O-linked N-acetylglucosamine transferase; DNMT1, DNA methyltransferase 1; JNK, c-Jun N-terminal kinase; p38 MAPK, p38 mitogen-activated protein kinase; AMPK, AMP-activated protein kinase; CBP/p300, CREB-binding protein/E1A-binding protein p300 (histone acetyltransferases); SIRT1/SIRT3, Sirtuin 1/Sirtuin 3; BDNF, Brain-derived neurotrophic factor; SKP2, S-phase kinase-associated protein 2; MDM2, Mouse double minute 2 homolog; NLRP3, NLR family pyrin domain containing 3 (inflammasome component); OS, Oxidative stress; O2▪-, superoxide anion; H2O2, hydrogen peroxide. Post-translational modifications (PTMs) of FOXO proteins: molecular switches determining activity and function. NOTE: ↑, Upregulation/Increase; ↓, Downregulation/Decrease; O2▪- is primarily generated at mitochondrial electron transport chain Complex I and III; H2O2 is produced by dismutation of O2▪- by SOD2 or directly by monoamine oxidase during dopamine catabolism. Abbreviations: HAT, histone acetyltransferase; NDDs, neurodegenerative diseases; OGT, O-linked N-acetylglucosamine transferase; DNMT1, DNA methyltransferase 1; JNK, c-Jun N-terminal kinase; p38 MAPK, p38 mitogen-activated protein kinase; AMPK, AMP-activated protein kinase; CBP/p300, CREB-binding protein/E1A-binding protein p300 (histone acetyltransferases); SIRT1/SIRT3, Sirtuin 1/Sirtuin 3; BDNF, Brain-derived neurotrophic factor; SKP2, S-phase kinase-associated protein 2; MDM2, Mouse double minute 2 homolog; NLRP3, NLR family pyrin domain containing 3 (inflammasome component); OS, Oxidative stress; O2▪-, superoxide anion; H2O2, hydrogen peroxide. Isoform-specific structural features determine distinct neuronal functions. FOXO6 lacks a C-terminal nuclear export signal, enabling constitutive nuclear residence and rapid response to synaptic calcium/IL-1β in forebrain neurons [37,38]. FOXO3 contains an alternatively spliced AMPK-phosphorylation site linking energy crisis to antioxidant gene induction in substantia nigra dopaminergic neurons. FOXO4 harbors an MDM2-binding motif for p53-dependent senescence in microglia; FOXO1's proline-rich extension enables PGC-1α interaction, coordinating metabolic reprogramming [27]. These architectural distinctions create a functional specialization matrix: FOXO1/metabolism, FOXO3/oxidative stress (OS) defense, FOXO4/cellular senescence [39], FOXO6/synaptic function [40] (disease-specific roles in Section 4 and Table 3). Table 3Cell-type-specific functions of FOXO proteins in the central nervous system: protective versus detrimental effects.Table 3Cell TypeIsoformPhysiological FunctionProtective pathwayPathological Activation (Diseases)Excitatory NeuronsFOXO1/3/6OS defense; Metabolic adaptationSOD2/CAT; PGC-1α, AutophagicApoptotic (AD) [10,41]; Energy depletion (PD) [42]; Synaptic dysfunction (HD) [19,27]Dopaminergic NeuronsFOXO1/3Mitochondrial quality; AntioxidantPINK1/Parkin; Fatty acidMitochondrial dysfunction; Oxidative damage ↑; Cell death (PD) [30,43].MicrogliaFOXO1Polarization; PhagocyticM2[104,110]; Aβ phagocytosis; A20Monocyte ↑↑; Chronic M1 ↑↑ (AD) [44,45]; Phagocytosis ↓ (PD) [46,47]FOXO3Inflammation regulationAntioxidant and Phagocytosis-related genePro-inflammatory cytokine ↑↑ [48]; NLRP3 ↑↑ (MS, ALS) [49,50]AstrocytesFOXO1Metabolic support; Glutamate homeostasismTORC1; EAAT2; Lipid dropletExcitotoxicity [51,52]; Glutamine synthetase ↓ (ALS) [[53], [54], [55]], Metabolic ↓ (AD) [12,13]OligodendrocytesFOXO3Myelin maintenance; Cell survivalAntioxidant; Mitochondrial functionApoptosis [56,57]; Demyelination (MS) [15]TregFOXO1/3Immune tolerance maintenanceFOXP3; ImmunosuppressiveTreg ↓; Autoimmune reactions ↑ (MS; NMOSD) [58,59]Th17FOXO1Pro-inflammatory cell differentiationTh17Th17 differentiation ↑ ↑; IL-17/IFN-γ ↑ ↑ (MS) [60,61]B cellsFOXO1Antibody productionB cell; Antibody switchingBCR ↑ ↑; Autoantibody ↑ ↑ (MS) [62,63]Abbreviations: CNS, central nervous system; DA, dopamine; EAAT2, excitatory amino acid transporter 2; Treg, regulatory T cell; Th17, T helper 17 cell; BBB, blood–brain barrier. mTORC1, mechanistic target of rapamycin complex 1. Cell-type-specific functions of FOXO proteins in the central nervous system: protective versus detrimental effects. Abbreviations: CNS, central nervous system; DA, dopamine; EAAT2, excitatory amino acid transporter 2; Treg, regulatory T cell; Th17, T helper 17 cell; BBB, blood–brain barrier. mTORC1, mechanistic target of rapamycin complex 1. Functionally, the four FOXO isoforms operate as a coordinated stress-sensing network, with activation thresholds calibrated to stimulus intensity. Pathological mechanisms shared by FOXO proteins in NDDs FOXO proteins decode cellular stress through conserved structural motifs. In pathological states, however, these regulatory circuits enter maladaptive feedback loops. Transient stress cues persist chronically, driving FOXO isoforms from adaptive sensors into sustained pathogenic effectors [64,65]. Rather than treating FOXO pathways as isolated cascades, this section organizes shared mechanisms into four sequential tiers of cellular stress response, with transition thresholds governed by PTM signatures and isoform competition (Table 1, Table 2, Table 3, Table 4). Neuronal stress responses follow a hierarchical progression. Initial cell-autonomous compensation gives way to glial recruitment, followed by autophagy-lysosomal surveillance, and ultimately, commitment to regulated cell death when homeostatic capacity is exhausted. This section follows FOXO proteins through these four stages, tracing how they transform from protective regulators into drivers of pathology. Tier I cell-autonomous homeostasis, represents initial, isolated neuronal adaptation through metabolic reprogramming and antioxidant defense [69]. Tier II Intercellular coordination, engages when individual defenses prove insufficient, recruiting microglial and astrocytic support through FOXO-mediated paracrine signaling [53,80,88]. Tier III Intracellular quality control, activates large-scale autophagic and lysosomal clearance as final self-renewal attempts [65,91]. Tier IV Cell fate decision, marks irreversible commitment to senescence or death programs when quality control fails [41]. Each tier builds upon yet partially supersedes preceding tiers, with transition governed by quantifiable molecular parameters including stress load, post-translational modification signatures, and isoform activity ratios. Table 2Context-dependent duality of FOXO signaling: stress intensity determines functional outcomes in neurodegeneration.Table 2Stress LevelStateTarget moleculeCellular FateDisease Stage/ModelBasal/MildFOXO1/3: Nuclear localizationSIRT1-mediated deacetylation [23,66]SOD2 [56], CAT [15,23], GPx/PRDX3 [56]Maintenance of redox homeostasis via scavenging of O2▪-/H2O2Healthy agingGADD45 [5,66]Genomic integrityEarly preventionPGC-1α [26,67], G6PD [35]ATP ↑Pre-diabetesULK1/Beclin-1 [65,68]Basal protein clearancePreclinical ADModerate/AcuteJNK phosphorylation activationPartial deacetylation [69,70]MnSOD ↑ [71], HO-1 ↑ [72]Resistance to mitochondrial O2▪-/H2O2 damageEarly AD,PD: Rotenone exposureLC3/p62 [65,73], LAMP2A [[74], [75], [76]]Misfolded proteins clearanceHD: Early mHTT aggregationPINK1, Parkin [77], MFN2 [26,78]Damaged mitochondria removalPD: α-syn mitochondrial toxicityIκBα↑ [79], A20↑ [46,47], NF-κB ↓ [79,80]Limitation of neuro-inflammationMS: Early EAE modelSustained/SevereExcessive nuclear accumulationSIRT1 - hyperacetylationPersistent JNK activation [41,81]Bim, FasL, PUMA [82]Mitochondrial pathway apoptosisLate AD/PDNLRP3, IL-1β, TNF-α [44,49,80]Neuroinflammation↑AD: Microglial overactivation_Lysosomal membrane rupture, Cell deathALS: FOXO3 ↑↑→ Motor neuron deathGLUT3↓ [83], PDK4↑ [84]Energy crisisAD: Brain glucose metabolism declineAbbreviations: SOD2,Superoxide dismutase 2;CAT,Catalase; GPx, Glutathione peroxidase;PRDX3,Peroxiredoxin 3;GADD45,Growth arrest and DNA damage-inducible 45;PGC-1α,Peroxisome proliferator-activated receptor γ coactivator 1α;G6PD, Glucose-6-phosphate dehydrogenase;ULK1,Unc-51 like autophagy activating kinase 1;LC3,Microtubule-associated protein 1 light chain 3;LAMP2A, Lysosome-associated membrane protein 2A;PINK1, PTEN-induced kinase 1;IκBα,Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor α;A20, TNF-α-induced protein 3;NF-κB, Nuclear factor kappa B;IL-1β, Interleukin-1β;TNF-α,Tumor necrosis factor α;GLUT3,Glucose transporter 3;PDK4, Pyruvate dehydrogenase kinase 4;Bim, Bcl-2 interacting mediator of cell death;FasL,Fas ligand;PUMA, p53 upregulated modulator of apoptosis. Context-dependent duality of FOXO signaling: stress intensity determines functional outcomes in neurodegeneration. Abbreviations: SOD2,Superoxide dismutase 2;CAT,Catalase; GPx, Glutathione peroxidase;PRDX3,Peroxiredoxin 3;GADD45,Growth arrest and DNA damage-inducible 45;PGC-1α,Peroxisome proliferator-activated receptor γ coactivator 1α;G6PD, Glucose-6-phosphate dehydrogenase;ULK1,Unc-51 like autophagy activating kinase 1;LC3,Microtubule-associated protein 1 light chain 3;LAMP2A, Lysosome-associated membrane protein 2A;PINK1, PTEN-induced kinase 1;IκBα,Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor α;A20, TNF-α-induced protein 3;NF-κB, Nuclear factor kappa B;IL-1β, Interleukin-1β;TNF-α,Tumor necrosis factor α;GLUT3,Glucose transporter 3;PDK4, Pyruvate dehydrogenase kinase 4;Bim, Bcl-2 interacting mediator of cell death;FasL,Fas ligand;PUMA, p53 upregulated modulator of apoptosis. Table 4Integrative regulatory networks: FOXO-centered signaling axes and therapeutic implications.Table 4AxisUp-downstream pathwaysMolecular MechanismDysregulation in DiseaseTherapeuticSIRT1-FOXOUp: NAD+ levels; Down: ntioxidant/anti-inflam genesSIRT1 deacetylates FOXO3 [49]Aging: NAD+↓ → SIRT1 ↓Resveratrol↑ DNA binding + chromatin occupancy [85]AD: Aβ → SIRT1 ↓NAD+ precursorspro-apoptotic genes ↑ [82,86]HD: mHTT→ SIRT1-FOXO1 ↓SIRT1-specific activatorsFOXO–NF–κBDown: Inflam genesFOXO competitive combination NF-κB [80]Chronic stress: FOXO ↑↑ → Inflam ↑HDAC inhibitorsIκBα ↑ → NF-κB cytoplasmic retention [87]AD: Aβ → NF-κB ↑↑Specific FOXO1 activatorsA20 ↑ → TLR4 ↓ [46,88]MS: Th17/Treg imbalanceCombined anti-inflamFOXO-PGC-1αUp: AMPK/InsulinDown: Mitochondrial genesFOXO1 binds PGC-1α promoter [35]PD: PGC-1α ↓ → Mito-dysfunctionGC-1NRF1/2-TFAM-mtDNA ↑ [26,89]HD: mHTT blocks FOXO1-PGC-1αPioglitazoneMitochondrial biogenesis + ETC assembly [26]Diabetes: Hyperglycemia → PGC-1α methylation ↓CRISPR-dCas9 demethylationFOXO-mTOR-AutophagyUp: Nutrient/energy sensingDown: Autophagy-lysosomalULK1 ↑ [65,90]AD: Lysosomal acidification↓RapamycinTFEB nuclear translocation → Lysosomal biogenesis [91,92]PD: α-syn ↑ → Autophagy ↓TrehaloseLAMP2A ↑ [65,74]HD: mHTT → autophagic flux ↓; ALS: TDP-43 ↑ + Autophagy ↓AlginateFOXO-Insulin/IGF-1Up: Insulin/IGF-1Down: Metabolic genesAKT phosphorylation → FOXO nuclear export [69,70,93]AD: Brain insulin resistance → FOXO1 ↑↑Intranasal insulinGlucose uptake ↑ [35,94]Hyperglycemia - cognitive impairment vicious cycleMetforminGluconeogenesis ↓ [35,95]Aging: IGF-1 signaling↓GLP-1 receptor agonistsAbbreviations:TFEB, transcription factor EB; GLP-1, glucagon-like peptide-1; PI3K, phosphoinositide 3-kinase; IGF-1, insulin-like growth factor-1. Integrative regulatory networks: FOXO-centered signaling axes and therapeutic implications. Abbreviations:TFEB, transcription factor EB; GLP-1, glucagon-like peptide-1; PI3K, phosphoinositide 3-kinase; IGF-1, insulin-like growth factor-1. Cell-autonomous homeostasis: Metabolic and redox adaptation When stress first appears, individual neurons deploy FOXO proteins to restore balance without outside assistance. This initial response relies on three coordinated functions: FOXO1 adjusts energy production and mitochondrial biogenesis, FOXO3 neutralizes oxidative damage and maintains neuronal survival, and FOXO6 maintains local fuel supplies at synapses. Whether FOXO activation yields neuroprotection or apoptosis hinges on both the magnitude and chronicity of cellular stress (Table 2). Energy sensing and mitochondrial biogenesis FOXO1 links nutritional status to mitochondrial capacity. Under mild metabolic stress, FOXO1 and FOXO3 directly bind to the PGC-1α promoter, initiating a cascade that drives mitochondrial biogenesis [96]; FOXO3 upregulates mitochondrial fusion proteins MFN2 and OPA1, thereby stimulating mitochondrial DNA replication and the assembly of ETC complexes, maintaining mitochondrial network integrity; and FOXO1-upregulated antioxidant enzymes (SOD2, CAT) mitigate mitochondrial ROS leakage: SOD2 dismutates O2▪- (from ETC Complex I) to H2O2, which CAT decomposes to H2O/O2. This negative feedback loop is reinforced by FOXO1-induced MFN2/OPA1 expression, maintaining mitochondrial network integrity to reduce ROS production [56]. This program proves especially critical in metabolically active neurons. In substantia nigra dopaminergic neurons, FOXO1-PGC-1α synergy enhances complex I activity, reducing sensitivity to mitochondrial toxins [30,43]. Beyond simply increasing mitochondrial mass, FOXO1 coordinates substrate switching. It induces PDK4 and CPT1A, pushing metabolism toward fatty acid oxidation and ketogenesis when glucose runs short [35,84]. In HD models, this metabolic flexibility helps striatal neurons maintain ATP production despite energy stress (Fig. 2) [97]. FDG-PET detects cerebral glucose hypometabolism in prodromal AD. This decline correlates with elevated CSF insulin resistance markers and increased hippocampal FOXO1 immunoreactivity in postmortem tissue [36]. Collectively, these human and imaging data implicate FOXO1-mediated metabolic reprogramming as a central driver of cerebral energy failure. FOXO-mediated mitochondrial quality control and metabolic regulation in neurons. This schematic illustrates the central role of FOXO transcription factors (predominantly FOXO1 and FOXO3) in coordinating four major regulatory branches of mitochondrial homeostasis. (1) Mitochondrial dynamics (First from left): FOXO proteins regulate membrane proteins (MP) promoting fusion (OPA1, MFN2) and fission (DRP1), enabling segregation of damaged mitochondrial segments to maintain network integrity. (2) Mitochondrial biogenesis (Second from left): FOXO1 directly enhances mitochondrial mass and electron transport chain (ETC) activity through transcriptional upregulation of mitochondrial genes. (3) Energy metabolism switching (Third from left): FOXO1 activates PDK4 and CPT1A, suppressing glycolysis (GLY↓) and promoting fatty acid oxidation (FA-OS), with ketone bodies (KB) providing alternative ATP production during energy deficit. (4) Mitochondrial transcription (Fourth from left): FOXO1 induces PGC-1α, which drives TFAM/NRF1/2-mediated upregulation of mitochondrial DNA (mtDNA) and ETC component expression. These coordinated pathways ensure neuronal mitochondrial homeostasis and energy supply under physiological and pathological conditions. Abbreviations: MFN2, mitofusin 2; NRF1/2, nuclear respiratory factor 1/2; OPA1, optic atrophy 1; PDK4, pyruvate dehydrogenase kinase 4; PGC-1α, peroxisome proliferator-activated receptor γ coactivator 1α; TFAM, transcription factor A, mitochondrial. FOXO-mediated mitochondrial repair operates through several interconnected modules. Firstly, FOXO drives mitochondrial biogenesis and enhances electron transport chain (ETC) function. Secondly, FOXO maintains the delicate balance between mitochondrial fission and fusion. It can upregulate fusion proteins like MFN2 and OPA1 to promote network connectivity and improve ETC efficiency under stress, while also facilitating the fission protein DRP1 to segregate damaged segments for degradation, a balance vital for synaptic integrity in early tauopathy and PD models (Fig. 2) [98]. FOXO1 operates mainly in the soma, regulating nuclear-encoded mitochondrial genes, but its effects travel outward. Enhanced mitochondrial transport carries these organelles to distal axons and synapses, preserving energy-intensive processes like synaptic transmission during metabolic challenge [78,99]. In AD, Aβ oligomers (AβOs) block FOXO3 nuclear translocation, exacerbating energy deficits [100]. Antioxidant defense and survival maintenance While FOXO1 manages energy supply, FOXO3 handles oxidative threat. This classic cytoprotective function responds dynamically to redox conditions through post-translational regulation (Table 1, Table 2). Under mild oxidative stress (physiological O2▪-/H2O2 levels), FOXO1 and FOXO3 orchestrate pro-survival transcriptional programs. The nuclear accumulation of FOXO3, which typically precedes overt neurodegeneration, is driven by three convergent inputs. First, low H2O2 inhibits AKT-mediated phosphorylation of FOXO1/3, releasing them from cytoplasmic 14-3-3 sequestration [101]. Second, concurrent JNK activation phosphorylates FOXO3 at Ser207 and Ser329, promoting nuclear import [102]. Third, AMPK-mediated phosphorylation links metabolic crisis to sustained nuclear retention [23,103]. These molecular changes are directly driven by ROS species: H2O2 inhibits AKT kinase activity through specific oxidation of the catalytic cysteine residue (Cys310 in the kinase activation loop and Cys124 in the pleckstrin homology domain), forming reversible sulfenic acid (-SOH) or irreversible sulfinic/sulfonic acid derivatives. These oxidative modifications disrupt AKT's ATP-binding affinity and phosphoinositide-dependent kinase-1 (PDK1) docking, reducing inhibitory phosphorylation of FOXO1/3 at Thr32, Ser253, and Ser315; O2▪-/H2O2 oxidize thioredoxin-1 (Trx1) at Cys32 and Cys35, inducing dissociation of the Trx1/ASK1 complex and activation of the ASK1-MKK4/7-JNK cascade, which phosphorylates FOXO3 at Ser207 and Ser329; and H2O2-induced DNA damage activates PARP-1, consuming NAD+ and limiting SIRT1-mediated FOXO3 deacetylation at Lys242 and Lys245 [102,[104], [105], [106]]. Nuclear FOXO3, deacetylated by SIRT1 (Table 1), enhances binding to the promoters of antioxidant genes (SOD2, CAT, HO-1) and autophagy-related genes (ULK1, Beclin-1), thereby maintaining redox homeostasis [71,107,108]. FOXO3 synergizes with NRF2 to induce HO-1, which breaks down heme into biliverdin—directly scavenging H2O2 and O2▪-—amplifying antioxidant capacity beyond individual pathway effects [72], initiates autophagy for misfolded protein clearance, and enhances DNA repair. Disease model relevance includes Aβ-induced lipid peroxidation protection in AD and rotenone toxicity mitigation via FOXO1-dependent thioredoxin in PD [42,109] (Fig. 3). Oxidative stress and antioxidant defense signaling network in early Alzheimer's (AD) and Parkinson's disease (PD). This diagram illustrates the protective cellular mechanisms underlying reactive oxygen species (ROS) scavenging and protein homeostasis in early-stage AD and PD. Endoplasmic reticulum (ER) stress induced by early pathological stimuli (Aβ oligomers in AD, α-synuclein aggregates in PD) leads to ROS accumulation (indicated by red glow). ROS are detoxified by antioxidant enzymes including catalase (CAT), glutathione peroxidase (GPx), manganese superoxide dismutase (MnSOD), and mitochondrial SOD2 through sequential conversion of superoxide anion (O2▪-) to hydrogen peroxide (H2O2) and ultimately to water (H2O). The transcription factor FOXO (FOXO1/FOXO3) plays a central regulatory role: SIRT1-mediated deacetylation activates FOXO to upregulate antioxidant enzyme expression, thereby inhibiting ROS production and oxidative damage. Additionally, FOXO activation induces NRF2 nuclear translocation and heme oxygenase-1 (HO-1) expression, further enhancing cellular antioxidant capacity. The insulin/PI3K/AKT pathway suppresses JNK activity to promote FOXO transcriptional function. Collectively, these protective pathways promote clearance of misfolded amyloid-β (Aβ) and α-synuclein (α-syn) proteins, reduce oxidative stress, and maintain neuronal homeostasis. Abbreviations: AKT, protein kinase B; ER, endoplasmic reticulum; JNK, c-Jun N-terminal kinase; NRF2, nuclear factor erythroid 2-related factor 2; PI3K, phosphoinositide 3-kinase; SOD2, superoxide dismutase 2. The FOXO3-SIRT1 interaction tunes this response. The SIRT1-FOXO3 axis strengthens DNA binding to antioxidant promoters while keeping pro-apoptotic genes silent (Table 2/4). The functional outcome is biased transcription: robust MnSOD, CAT, and autophagy gene expression, with concurrent Bim, FasL, and PUMA suppression. Successful stress resolution maintains SIRT1 activity, creating a self-sustaining protective loop. Under mild stress, FOXO activation promotes pro-survival and repair programs. This involves the upregulation of DNA repair enzymes like GADD45, molecular chaperones such as HSP70, and anti-apoptotic proteins including Bcl-xL, which help preserve mitochondrial integrity [110,111]. FOXO3 can also dissociate from HDAC2, activating p21 to promote a survival state in neurons [112]. Mechanistically, this survival bias is often associated with specific PTMs; for example, SIRT1-mediated deacetylation of FOXO3 enhances its binding to protective gene promoters while suppressing pro-apoptotic targets [66]. As detailed in Section 4.1.2, mild stress activates protective FOXO3 responses, whereas chronic stress triggers apoptotic conversion [113,114]. The SIRT1-FOXO axis generally promotes survival under manageable stress. Its impairment, as in ALS, leads to hyperacetylated FOXO3 exacerbating TAR DNA-binding protein 43 (TDP-43) toxicity [115]. Mechanistically extending this axis, SIRT1 also directly deacetylates mitochondrial proteins, creating a multi-layered protective response that declines with age-related NAD+ depletion [25,31,56]. FOXO3 tailors its activity to the neuronal environment. Its nuclear accumulation exemplifies this regulatory mechanism, which is governed by the dynamic balance between nuclear import and export signals. Metabolic flexibility and substrate switching FOXO6 coordinates synapse-specific metabolic support by maintaining constitutive nuclear residence and rapidly regulating GLUT3 expression to match local calcium influx and energy demands [116]. This isoform-specific synaptic metabolic coupling is integrated into the cell-type functional matrix in Table 3. In AD, this compensation initially offsets Aβ-induced hypometabolism, though later it contributes to inflammatory amplification [99]. Together, FOXO1, FOXO3, and FOXO6 form an integrated metabolic-redox module. FOXO1 builds long-term energy infrastructure and maintains mitochondrial dynamics, FOXO3 provides immediate ROS neutralization and survival signaling, and FOXO6 sustains local synaptic supply [117,118]. Functional redundancy ensures robustness, while isoform-specific features permit tailored responses to distinct challenges. Neurons advance to the next stage when this trio cannot restore balance. Persistent ROS elevation, ATP depletion, or accumulating damaged proteins signal solitary defense has failed. FOXO3 then releases specific miRNAs and inflammatory mediators that recruit microglia and astrocytes [119], opening the second stage described in Section 4.2. Transition thresholds vary by neuronal population. Substantia nigra dopaminergic neurons carry high intrinsic oxidative metabolism and limited antioxidant reserves, giving them low thresholds and explaining their selective vulnerability in PD (A detailed description is provided in Section 5.2). Cortical pyramidal neurons maintain more robust defenses and higher thresholds for external recruitment, contributing to their relative sparing in early disease stages. Intercellular coordination: Neuron-glia metabolic-immune dialogue Failure of intrinsic neuronal defenses triggers a shift toward microenvironmental recruitment, engaging glial support pathways. Initially activated intracellularly, FOXO proteins now initiate paracrine and endocrine signals that coordinate the broader neuro-glia-vascular unit [120]. This transition marks a fundamental shift from self-preservation to collective defense, leveraging microglial and astrocytic functions to amplify stress resolution. Beyond their established roles in OS, FOXO proteins act as pivotal, context-dependent regulators of neuroinflammation—a ubiquitous driver of pathology across NDDs [45]. Their functional roles transcend a simple pro- or anti-inflammatory dichotomy; instead, specific FOXO isoforms integrate microenvironmental cues to either suppress maladaptive inflammation or, under conditions of chronic dysregulation, inadvertently exacerbate it (summarized in Table 2, Table 3) [[121], [122], [123]]. Neuron-to-microglia communication FOXO proteins exert cell-type-specific functions in the central nervous system (summarized in Table 3). The earliest and best-characterized intercellular FOXO axis operates between stressed neurons and resident microglia. When neuronal FOXO3 activation exceeds autonomous resolution capacity, it initiates paracrine signaling that fundamentally reshapes microglial phenotype and functional output. Neuronal FOXO3 activation exceeds autonomous resolution capacity. It initiates paracrine signaling that fundamentally reshapes microglial phenotype. Neuronal FOXO employs two mechanisms to suppress NF-κB signaling. First, it competes directly with p65 for promoter binding [9,80]. Second, it upregulates IκBα, which sequesters NF-κB in the cytoplasm [124,125]. Such glial reprogramming amplifies tissue-wide defense. The functional outcome of this NF-κB suppression is microglial M2 polarization. FOXO signaling suppresses M1 markers by inhibiting NF-κB: iNOS generates NO, which reacts with O2▪- to form toxic ONOO−; FOXO3 competes with p65 for promoter binding and upregulates IκBα, reducing iNOS expression and ONOO−production. This shifts microglia to M2 polarization (arginase-1, IL-10) that clears Aβ aggregates [45,126]. This phenotypic shift expands microglial phagocytic capacity for Aβ and early protein aggregates (Fig. 4, Upper panel). Specifically, neuronal FOXO1 promotes a phagocytic M2 phenotype via PPARγ activation in early AD [127,128] and upregulates the deubiquitinase A20 to dampen α-synuclein-triggered microglial activation via the TLR4-MyD88-NF-κB (Toll-like receptor 4 – Myeloid differentiation primary response 88 – Nuclear factor kappa B signaling pathway) cascade in PD [46,47]. Conversely, microglial FOXO3 deficiency impairs phagocytosis and exacerbates pro-inflammatory cytokine release, hindering aggregate clearance [129,130]. SIRT1-FOXO–NF–κB axis modulates microglial polarization and neuroinflammation under different stress conditions. This figure illustrates the dual regulatory functions of the SIRT1-FOXO–NF–κB signaling pathway in neuroinflammatory responses under mild versus chronic stress conditions, presented as two contrasting panels. Upper panel — Mild/Acute stress (protective response): Adequate NAD+ sustains robust SIRT1 deacetylase activity, which deacetylates FOXO3 at conserved lysine residues (Lys242 and Lys245). Activated FOXO competitively binds NF-κB p65 subunit, upregulates IκBα expression to sequester NF-κB in the cytoplasm, and suppresses pro-apoptotic genes (Bim/PUMA) while inducing antioxidant enzymes (SOD2/CAT). This cascade increases anti-inflammatory cytokine production (IL-10, TGF-β), promoting M2 microglial polarization (alternatively activated, neuroprotective phenotype) and attenuating neuroinflammation. Lower panel — Aging/Chronic stress (pathological response): NAD+ depletion and persistent oxidative stress impair SIRT1 activity, leading to FOXO3 hyperacetylation and loss of NF-κB antagonism. NF-κB translocates to the nucleus, driving pro-inflammatory gene transcription (iNOS, TNF-α, IL-1β, IL-6). Concurrently, JNK-mediated FOXO phosphorylation shifts transcriptional output toward pro-apoptotic targets. The resulting M1 microglial polarization (classically activated, neurotoxic phenotype) amplifies neuroinflammation and accelerates neurodegeneration. Abbreviations: Bim, Bcl-2 interacting mediator of cell death; IκBα, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha; IL-10, interleukin 10; M1/M2, microglial polarization states; NAD+, nicotinamide adenine dinucleotide; NF-κB, nuclear factor kappa B; PUMA, p53 upregulated modulator of apoptosis; TGF-β, transforming growth factor beta. The efficacy of this intercellular axis depends on the PTM-dependent functional state of FOXO, as detailed in Table 4. Age- or disease-associated metabolic shifts disrupt the FOXO–SIRT1–NF-κB regulatory axis, shifting microglial balance toward chronic M1 activation and neuroinflammation in AD and HD (Fig. 4, Lower panel) [131]. Thus, neuronal FOXO signaling does not merely respond to local stress but actively orchestrates a tissue-wide defensive perimeter, leveraging glial plasticity to contain pathology before it escalates. Neuron-to-astrocyte metabolic coupling Parallel to microglial engagement, neurons signal astrocytes through metabolic rather than immunological channels. This dialogue centers on glutamate homeostasis and excitotoxic risk management, with FOXO1 as the principal neuronal mediator. Neuronal FOXO1 activation downregulates EAAT2/GLT-1 under metabolic stress, triggering compensatory astrocytic uptake and establishing a neuro-astrocytic metabolic division of labor [132,133]. Astrocyte-specific FOXO1 functions in glutamate homeostasis and metabolic support are summarized in Table 3; the intercellular coupling mechanism is detailed in Section 4.2.2. Metabolic reprogramming is another critical lever through which FOXO modulates inflammatory tone. In activated astrocytes, FOXO1 inhibits the mTORC1 pathway, shifting cell metabolism from aerobic glycolysis toward oxidative phosphorylation, a transition associated with a less inflammatory state [13]. Conversely, the loss of FOXO1 in astrocytes reduces excitatory amino acid transporter 2 (EAAT2) expression, leading to glutamate excitotoxicity that can secondarily fuel neuroinflammation. In ALS, FOXO1 hyperactivation in motor neurons epigenetically suppresses EAAT2 through HDAC1 recruitment, impairing glutamate clearance [53,54]. In superoxide dismutase 1 (SOD1)-G93A mice, blocking neuronal FOXO1 nuclear entry restored EAAT2, reduced extracellular glutamate, and attenuated motor neuron loss [18]. This demonstrates how disruption of neuro-astrocytic dialogue by excessive FOXO1 activation transforms protective coupling into pathological excitotoxicity amplification. Glia-to-neuron feedback and adaptive immunity This dialogue runs both ways. Glial cells provide metabolic feedback that sustains or suppresses neuronal FOXO activity, creating dynamic regulatory loops determining community defense duration and intensity. Microglia-derived IGF-1 engages the PI3K/AKT–FOXO axis to provide negative feedback on stress signaling [[134], [135], [136]], while failure to resolve inflammation sustains JNK/p38-mediated FOXO activation (Table 1, Table 2). Conversely, astrocyte-derived metabolites modulate SIRT1 activity, thereby tuning FOXO3 deacetylation status and stress resilience [66,97]. (see Section 4.1.2 for PTM-specific mechanisms). The most complex layer of FOXO's regulation is its cell-type-specific and often paradoxical role in immune cells (Table 3). In adaptive immunity, FOXO1 is crucial for maintaining immune tolerance. It curbs the differentiation of encephalitogenic Th17 cells and, in concert with FOXO3, stabilizes FOXP3 expression in Tregs, preserving their immunosuppressive function—a mechanism whose failure is implicated in MS [137]. FOXO3 can also activate indoleamine 2,3-dioxygenase (IDO), catalyzing the conversion of tryptophan to kynurenine, which suppresses T-cell proliferation and supports regulatory T cell (Treg) function [136,138]. However, in B cells, dysregulated FOXO1 activity can contribute to autoantibody production [139], highlighting its cell-context-dependent nature. Spatial organization matters. In healthy brain, astrocytic endfeet envelop synapses and vessels, creating metabolic microdomains where local substrate availability rapidly modulates neuronal FOXO status [140]. In neurodegenerative disease, astrocyte reactivity, microglial migration, or blood-brain barrier compromise disrupt this architecture, impairing feedback fidelity and contributing to uncontrolled FOXO activation [141,142]. If glial support cannot resolve damage, the system shifts to stage three. FOXO proteins now activate autophagy and lysosomal systems for final internal repair attempts before cell death commitment [91]. This transition shows molecular signatures: FOXO1 suppresses mTORC1, FOXO3 activates PINK1 and Parkin, and lysosomes build up coordinately, detailed in Section 4.3. Tier II strategies leverage collective neuro-glia resilience rather than targeting single neurons. Enhancing neuronal FOXO3-NF-κB antagonism, restoring neuro-astrocytic metabolic coupling, or promoting M2 polarization all amplify endogenous defense beyond intrinsic neuronal limits [80,143]. The Sir2 deacetylase modulates organismal life-span in various species. However, the molecular mechanisms by which Sir2 increases longevity are largely unknown. We show that in mammalian cells, the Sir2 homolog SIRT1 appears to control the cellular response to stress by regulating the FOXO family of Forkhead transcription factors, a family of proteins that function as sensors of the insulin signaling pathway and as regulators of organismal longevity. SIRT1 and the FOXO transcription factor FOXO3 formed a complex in cells in response to OS, and SIRT1 deacetylated FOXO3 in vitro and within cells. SIRT1 had a dual effect on FOXO3 function: SIRT1 increased FOXO3's ability to induce cell cycle arrest and resistance to OS but inhibited FOXO3's ability to induce cell death [66,144]. Thus, one way in which members of the Sir2 family of proteins may increase organismal longevity is by tipping FOXO-dependent responses away from apoptosis and toward stress resistance. But these interventions are time-sensitive, effective only while glial populations retain plasticity and before pathological feedback loops entrench. Intracellular quality control: Autophagy-lysosome surveillance When neuro-glia dialogue fails to resolve accumulated damage, the system transitions to autonomous, large-scale clearance operating without external support. This stage represents final self-renewal attempts through systematic degradation and recycling of damaged macromolecules, dysfunctional organelles, and protein aggregates. FOXO1 and FOXO3 serve as master regulators, coordinating autophagy biogenesis, cargo recognition, and execution with lysosomal degradation capacity. Success restores homeostasis; failure precipitates irreversible commitment to degeneration or death as described in Section 4.4. Hierarchical clearance FOXO-regulated quality control employs three coordinated clearance modalities, each specialized for distinct substrates and stress intensities (Table 4). This hierarchical organization ensures efficient resource allocation, with broad clearance preceding targeted, energy-intensive degradation. FOXO1 initiates macroautophagy by directly upregulating ULK1, Beclin-1, and LC3, while concurrent mTORC1 inhibition relieves ULK1 phosphorylation to permit autophagosome nucleation (Fig. 5, Top gray-blue pathway) [51,52,91]. The upstream signaling inputs and downstream autophagy-lysosomal targets of this axis are systematically consolidated in Table 4. Transcriptional priming plus post-translational disinhibition ensures rapid, robust activation. FOXO-mediated autophagy pathways in neuronal protection. This schematic illustrates three distinct but coordinated FOXO-dependent autophagy mechanisms that converge to provide neuroprotection against proteinopathies and mitochondrial dysfunction in neurodegenerative diseases. Top gray-blue pathway — Canonical macroautophagy (FOXO1-dependent): Under energy stress or nutrient deprivation, FOXO1 transcriptionally upregulates ULK1 and Beclin-1 while concurrently inhibiting mTORC1 kinase activity. mTORC1 disinhibition relieves ULK1 phosphorylation at Ser757, permitting autophagosome nucleation and LC3 lipidation, thereby initiating bulk degradation of cytoplasmic components. Middle green pathway — Selective mitophagy (FOXO3-dependent): When mitochondrial damage, FOXO3 enters the nucleus and transcriptionally upregulates Parkin E3 ubiquitin ligase, amplifying the PINK1/Parkin mitophagy signal. Concurrently, FOXO3 induces autophagy receptors (NDP52, optineurin) that bridge ubiquitinated mitochondria to LC3-positive phagophores, enabling selective degradation of damaged organelles. Bottom light brown pathway — Chaperone-mediated autophagy (FOXO1-dependent): FOXO1 induces LAMP2A (lysosome-associated membrane protein 2A), the rate-limiting receptor for chaperone-mediated autophagy (CMA). HSC70 chaperone recognizes the KFERQ-like motif on substrate proteins (α-synuclein, tau, mutant huntingtin) and delivers them directly to the lysosomal membrane for translocation and degradation, bypassing autophagosome formation. Collectively, these coordinated autophagic responses maintain cellular proteostasis, mitochondrial quality, and ultimately confer neuroprotection. Abbreviations: HSC70, heat shock cognate 70 kDa protein; LAMP2A, lysosome-associated membrane protein 2A; LC3, microtubule-associated protein 1 light chain 3; mHTT, mutant huntingtin; mTORC1, mechanistic target of rapamycin complex 1; NDP52, nuclear dot protein 52; PINK1, PTEN-induced kinase 1; ULK1, Unc-51 like autophagy activating kinase 1. Context determines FOXO1-driven macroautophagy significance. In early AD, enhanced autophagosome formation facilitates AβO clearance and reduces synaptic toxicity [145]. FOXO1 activation in response to AβO promotes the autophagic clearance of both Aβ and hyperphosphorylated tau [74,146]. But efficacy depends on autophagic flux completion: successful autophagosome-lysosome fusion and cargo degradation. Persistent autophagosome accumulation without lysosomal clearance, as seen in advanced HD, signals system failure and contributes to neuronal dysfunction [85]. Postmortem AD brain studies show progressive lysosomal dysfunction that correlates with FOXO3 nuclear accumulation in plaque-adjacent neurons [147]. Whether this accumulation reflects a protective response or pathological exhaustion remains unclear. Longitudinal biomarker studies are needed to resolve this ambiguity. Mitophagy execution provides the second, organelle-specific clearance tier, governed primarily by FOXO3. Upon mitochondrial damage detected through membrane depolarization and PINK1 accumulation, FOXO3 enters the nucleus and transcriptionally upregulates Parkin, amplifying the PINK1/Parkin mitophagy signal [148]. Concurrently, FOXO3 directly regulates autophagy receptors including optineurin and NDP52, which bridge ubiquitinated mitochondria to LC3-decorated phagophores for selective degradation [91]. This coordinated clearance is particularly salient in PD, where FOXO3-dependent mitophagy attenuates α-syn-induced neurodegeneration by eliminating damaged, ROS-generating mitochondria [149] (Fig. 5, Middle green pathway). The FOXO3-PINK1/Parkin axis proves especially important in dopaminergic neurons, where mitochondrial quality control is essential given high metabolic demand and oxidative burden [150,151]. In PD models, FOXO3-dependent mitophagy clears damaged mitochondria that accumulate O2▪-​/H2​O2​: FOXO3 upregulates PINK1/Parkin, which tag depolarized mitochondria for autophagic degradation, eliminating the source of chronic ROS [10,152]. This mechanism partners with stage one mitochondrial biogenesis (Section 4.1.1), FOXO1-driven new mitochondria generation and FOXO3-driven damaged mitochondria clearance together maintain mitochondrial population quality [78,153]. Chaperone-mediated autophagy (CMA) constitutes the third, highly selective clearance tier. FOXO1 regulates CMA capacity through transcriptional control of LAMP2A, the rate-limiting receptor for CMA substrate recognition [[74], [75], [76]]. Unlike bulk macroautophagy degradation, CMA permits targeted elimination of specific proteins—α-syn, tau, mHTT—that evade proteasomal degradation and would otherwise form toxic aggregates (Fig. 5, Bottom light brown pathway) [[154], [155], [156]]. This three-tier hierarchy ensures proportional resource allocation: macroautophagy addresses acute, large-scale damage; mitophagy maintains organelle quality; CMA provides precision clearance of specific pathogenic proteins. FOXO1 and FOXO3 coordinate through differential target gene regulation: FOXO1 emphasizes autophagosome biogenesis and CMA capacity, while FOXO3 prioritizes mitochondrial quality control. Autophagic flux maintenance Tier III efficacy depends not merely on autophagy initiation but on complete autophagic flux: seamless progression from cargo recognition through lysosomal degradation. FOXO proteins regulate this flux through lysosomal acidification control and transcription factor EB (TFEB)-mediated lysosomal biogenesis (Table 4). Direct lysosomal acidification is regulated by FOXO3 through transcriptional upregulation of vacuolar H+-ATPase (v-ATPase) subunits. Lysosomal acidification is essential for hydrolase activation and efficient cargo degradation; impairment, as seen in tauopathies, causes undigested material accumulation and lysosomal membrane permeabilization [148,150]. In AD, FOXO3 helps restore lysosomal acidity by upregulating v-ATPase subunits, thereby supporting the cathepsin-mediated degradation of pathological tau [157,158]. FOXO3-mediated v-ATPase upregulation proves particularly critical in aging neurons, where lysosomal pH drifts alkaline due to accumulated membrane damage and proton leak. Restoring acidic pH enhances degradative capacity and prevents pathological lysosomal dysfunction consequences, including iron release and ferroptosis induction [159]. TFEB-mediated lysosomal biogenesis provides a parallel, FOXO1-regulated pathway for long-term clearance capacity expansion. In HD, mHTT impairs TFEB nuclear translocation, blocking lysosomal biogenesis and compromising handling of accumulating protein aggregates. FOXO1 facilitates TFEB nuclear import through calcineurin activation, restoring lysosomal gene expression and enhancing autophagosome-lysosome fusion [160]. FOXO1-TFEB coordination exemplifies systems-level Tier III regulation: FOXO1 ensures adequate lysosomal infrastructure, FOXO3 maintains immediate degradative efficiency. Disruption of either lysosomal acidification or TFEB-driven biogenesis precipitates autophagic stress. This stress manifests as autophagosome accumulation without proportional cargo degradation. Under conditions of sustained and severe stress, this adaptive response can devolve into a maladaptive one. Chronic FOXO activation may lead to an overload of the autophagy-lysosomal system, depleting essential components or causing lysosomal membrane rupture, which releases hydrolytic enzymes and exacerbates cellular damage [65,161]. This detrimental switch is evident in ALS, where initial FOXO3-enhanced autophagy aimed at clearing TDP-43 aggregates, when persistently hyperactivated, exhausts the autophagic machinery and accelerates motor neuron death. The shift is often driven by altered signaling context, such as sustained JNK activation, which phosphorylates FOXO and may promote non-selective, excessive autophagy [162]. Epigenetic programming of clearance capacity Tier III quality control carries distinctive susceptibility to long-term epigenetic programming, establishing metabolic memory that influences clearance capacity across lifespan and potentially generations. The FOXO-SIRT1 axis serves as the primary molecular substrate, with acetylation dynamics encoding functional states persisting beyond transient stress resolution (Table 5, Table 4). Table 5Mechanisms of epigenetic regulation in NDDs.Table 5DiseaseTarget MoleculeEpigenetic MechanismModelExperimental ConditionEffectNormalPTMsSIRT1 mediates FOXO deacetylationHEK293 cells, SH-SY5Y neurons, mouse tissuesPhysiological state, mild OS, SIRT1 ↑↑ epigenetic regulation [29,64,66]Pathogenic proteins→ FOXO aberrant acetylation/phosphorylationAD/HD patient brain tissues, cellular modelsAβ treatment, mHTT ↑, OS, aging↓ target gene regulation [81,113,163]ADHistone modificationFOXO3 → p300→ positive feedback loopAD patient hippocampus, APP/PS1 mice, primary neuronsAβO treatment, HDAC2 ↑, OSFOXO3 ↑ + ↓ neuro-inflam [8,9,32,71]FOXO1 stabilizes miR-132→ ↓ HDAC2HEK293 cells, AD mouse models, patient brain tissueAβ25-35 treatment, FOXO1 ↑↑↑ histone acetylation→regulation of tau [114,146,164,165]DNA methylationFOXO3 + DNMT1 → methylationBV2 microglia, AD mouse modelsLPS → inflammation, Aβ stimulation↓ NLRP3→↓neuro-inflam [33,44,49,166]lncRNAFOXO1 stabilizes miR-132→ ↓ HDAC2SH-SY5Y cells, AD transgenic miceOS, Aβ treatmentRegulation of tau phosphorylation [164,167,168]Pathological triggersAβ → ↑ HDAC2/DNMTs + aberrant FOXO modifications5×FAD mice, AD patient brain tissue, primary neuronsOS, Aβ treatment↓ neuroprotective genes +↑ inflam/tau [114,169]HDHistone modificationFOXO3 + CBP/p300 bromodomain → ↑HATHD patient striatum, R6/2 mice, iPSCsmHTT ↑↑, CBP dysfunction↑BDNF →↑neuronal survival [28,29,97,170]DNA methylationFOXO1 → ↑ TET2 → ↑ demethylationHD cellular models, R6/2 miceMitochondrial dysfunction, OS↑ mitochondrial gene→↑ energy metabolism [31,35,95]Pathological triggermHTT →↓ CBP/p300 + ↑ DNMTsHD patient brain tissue, R6/2 mice, YAC128 micemHTT ↑↑↓BDNF + energy metabolism↓ [27,160,170]PDlncRNAMolecular chaperone lncRNA→↑ FOXO1 binding α-synMPTP-treated mice, SH-SY5Y cells, PD patient blood exosomesMPTP/MPP + treatment, α-syn ↑ ↑↓α-syn →↓protein aggregation [168,171,172]Pathological triggersα-syn → HAT/HDAC balancePD patient substantia nigra, α-syn transgenic mice, cell modelsα-syn ↑↑, mitochondrial dysfunctionPathogenic protein ↑↑ → vicious circle [15,98,173]NOTE: Epigenetic modifications including histone acetylation, DNA methylation, and non-coding RNA regulation modulate FOXO transcriptional activity in a disease-specific manner. These epigenetic programs establish long-lasting molecular memory that contributes to disease initiation and progression.Abbreviations:miRNA, microRNA; lncRNA, long non-coding RNA; TET2, ten-eleven translocation 2. Mechanisms of epigenetic regulation in NDDs. NOTE: Epigenetic modifications including histone acetylation, DNA methylation, and non-coding RNA regulation modulate FOXO transcriptional activity in a disease-specific manner. These epigenetic programs establish long-lasting molecular memory that contributes to disease initiation and progression. Abbreviations:miRNA, microRNA; lncRNA, long non-coding RNA; TET2, ten-eleven translocation 2. Epigenetic programming of clearance capacity is tightly coupled to the SIRT1–FOXO acetylation dynamics (Table 1, Table 4). While SIRT1 activators enhance protective deacetylation and autophagic flux [174], chronic stress promotes FOXO3 hyperacetylation and JNK-mediated phosphorylation, driving a functional switch from autophagy promotion to pro-apoptotic execution (Table 2, Section 4.4.1). In ALS spinal motor neurons, this acetylation shift correlates with TDP-43 proteinopathy progression and autophagy failure [161,175]. DNA methylation patterns constitute a more stable epigenetic layer. FOXO1 interacts with DNA methyltransferase 3A (DNMT3A) to hypermethylate the PGC-1α promoter under hyperglycemic conditions, permanently suppressing mitochondrial biogenesis and, by extension, metabolic resources required for sustained autophagy [176,177]. This epigenetic silencing creates a vicious cycle: reduced mitochondrial capacity increases autophagy reliance, while autophagy itself is compromised by metabolic insufficiency. Stage three outcome—recovery or death—depends on cleanup efficacy. Restoring autophagic flow through SIRT1 activation, TFEB enhancement, or pharmacological intervention allows neurons to return to normal surveillance [91,92]. But when autophagosomes accumulate undigested, lysosomal membranes rupture, and cathepsins leak into the cytoplasm, FOXO-mediated death programs activate. This shift reveals itself through JNK-mediated FOXO phosphorylation, p53 activation, and Bim/FasL induction, as detailed in Section 4.4 [178,179]. Tier III therapeutic implications center on autophagic flux restoration rather than mere autophagy induction. Strategies enhancing lysosomal acidification, promoting TFEB nuclear translocation, or sustaining SIRT1-mediated FOXO deacetylation address bottleneck steps determining system efficacy. However, these interventions are strictly stage-dependent: effective in early disease with intact autophagic machinery, but potentially futile or harmful when lysosomal function is severely compromised. Cell fate decision: from protection to death When hierarchical quality control exhausts capacity without achieving stress resolution, cellular programs transition irreversibly to active commitment to elimination. This stage represents not passive failure but an evolutionarily conserved, regulated process removing damaged cells to preserve tissue integrity and prevent inflammatory collateral damage [1,8]. FOXO proteins, functioning through previous stages as adaptive stress responders, now undergo fundamental functional transformation to become executioners of programmed cell death [66,82]. This transition is governed by a molecular switch converting FOXO proteins from pro-survival to pro-apoptotic regulators through discrete PTM, isoform competition dynamics, and epigenetic state changes. Understanding this switch, and its pharmacological modulation potential, represents a critical challenge in neurodegenerative disease therapeutics. Post-translational modification switch FOXO protein functional identity is encoded primarily by post-translational modification state, determining promoter occupancy, transcriptional output, and protein-protein interaction profiles (Table 1). The protective-to-death transition is marked by characteristic PTM signature shift: from SIRT1-mediated deacetylation toward JNK-mediated phosphorylation. The protective-to-death transition is governed by a discrete shift in FOXO PTM signatures, shifting from SIRT1-mediated deacetylation toward JNK-mediated phosphorylation (Table 1, Table 2). Under manageable stress, SIRT1 dominance maintains nuclear FOXO3 in a deacetylated, pro-survival state (Fig. 6, Left panel). Chronic/unresolvable stress with sustained O2▪-/H2O2 accumulation specifically oxidizes the redox-active cysteine residues of Trx1 (Section 4.1.2), forming an intramolecular disulfide bond. This conformational change dissociates the Trx1/ASK1 inhibitory complex, exposing ASK1's activation loop for autophosphorylation at Thr838 [6,180]. Concomitantly, H2O2-induced DNA damage hyperactivates PARP-1, depleting NAD+ and impairing SIRT1 deacetylase activity. The resulting hyperacetylated FOXO3 switches DNA-binding preference from antioxidant promoters to pro-apoptotic targets (Bim, FasL) [86,152,181]. Cell-type-specific and stress-dependent roles of FOXO transcription factors in neuronal survival and death. This diagram illustrates the divergent functional outcomes of FOXO proteins under varying stress conditions and in distinct neuronal subtypes, presented as two contrasting scenarios. Left panel — Excitatory cortical neurons under mild oxidative stress: AKT-mediated phosphorylation of FOXO3 at Thr32, Ser253, and Ser315 promotes 14-3-3 scaffold protein binding and cytoplasmic retention (sequestration), limiting nuclear transcriptional activity. Concurrently, HDAC2 facilitates FOXO3 nuclear export. The small fraction of nuclear FOXO3 is deacetylated by SIRT1, enabling transcription of pro-survival genes (p21, antioxidant enzymes, DNA repair factors) while suppressing pro-apoptotic targets. Cytoplasmic FOXO3 additionally induces p21 expression through non-transcriptional mechanisms, collectively promoting neuronal survival, synaptic maintenance, and stress resistance. Right panel — Dopaminergic substantia nigra neurons under significant stress or chronic disease progression: Chronic oxidative stress and mitochondrial dysfunction overwhelm AKT-mediated inhibitory phosphorylation. FOXO1 translocates to the nucleus and transcriptionally upregulates Bim (Bcl-2 interacting mediator of cell death). Bim displaces anti-apoptotic Bcl-2 from Bax/Bak complexes, triggering mitochondrial outer membrane permeabilization, cytochrome c (Cyt C) release, and caspase-9/-3 activation, ultimately executing apoptosis. Concurrently, Bim promotes α-synuclein aggregation through disruption of mitochondrial dynamics, exacerbating neurodegeneration in Parkinson's disease. Key transition mechanisms: The functional switch from neuroprotection to neurodegeneration is governed by (i) stress intensity and duration, (ii) PTM signature shifts (AKT-phosphorylation vs. JNK-phosphorylation), (iii) SIRT1 activity status (NAD+ availability), and (iv) cell-type-specific cofactor expression. Abbreviations: 14-3-3, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein; Bcl-2, B-cell lymphoma 2; HDAC2, histone deacetylase 2; P, phosphorylation; PTM, post-translational modification. In scenarios of significant stress or during progression of chronic disease, FOXO function transitions to favor pro-apoptotic pathways. Studies demonstrate that in advanced PD, sustained FOXO1 activation in substantia nigra dopaminergic neurons correlates with elevated Bim expression, which alongside α-syn aggregation promotes neuronal apoptosis [10,13,182]. FOXO1 increases Bim expression, resulting in competition with anti-apoptotic Bcl-2. As pro-apoptotic signals exceed inhibitory signals, alterations in mitochondrial membrane permeability occur, leading to cytochrome c (Cyt C) release and caspase activation, ultimately resulting in neuronal cell death, in right panel of Fig. 6 [1,2]. This stress-dependent "molecular switch" positions FOXO as a critical regulator of neuronal stress responses. SIRT1-JNK competition for FOXO PTM control determines cell fate. In early disease, SIRT1 activators maintain protective FOXO deacetylation and delay stage four entry [183]. In advanced stages, persistent JNK activation, driven by chronic OS, mitochondrial dysfunction, or protein aggregation, overwhelms SIRT1 capacity, establishing stable pro-apoptotic FOXO phosphorylation. This PTM-encoded commitment point is functionally irreversible: even if initial stressors are subsequently removed, JNK-phosphorylated FOXO maintains death program execution. The AKT pathway adds further regulatory complexity, with distinct effects in neurons versus glial cells. In motor neurons, AKT phosphorylation of FOXO reduces transcriptional activity and promotes cell survival —this mechanism was first characterized by Bouchard et al. and involves AKT-mediated phosphorylation at conserved C-terminal sites (Section 3) promotes cytoplasmic retention. In HD, decreased insulin signaling in striatal medium spiny neurons reduces AKT function, subsequently leading to the nuclear relocation of FOXO1 and the activation of caspase-8-dependent cell death pathways [81,115]. Conversely, SIRT1-mediated FOXO3 deacetylation (Section 4.1.2) enhances pro-survival gene interactions [29,184,185]. In ALS, impairment of the SIRT1-FOXO3 pathway in spinal motor neurons reduces their ability to withstand TDP-43 toxicity [54,161]. In microglia, excessive FOXO3 activity triggers CCL2 secretion, which recruits peripheral monocytes and exacerbates inflammation [88,186]. This cell-type specificity explains why identical FOXO modifications yield divergent outcomes. Studies further demonstrated that FOXO3 can interact directly with ATM kinase in response to DNA damage, thereby activating the p53 pathway to induce neuronal apoptosis [13]. The interaction between JNK and FOXO4 in cortical neurons in tauopathies facilitates tau hyperphosphorylation and triggers FasL-Fas-mediated apoptotic pathways [187,188]. These cell-type-specific interactions render FOXO functions highly context-dependent, highlighting the need for disease-specific analysis to discern dominant regulatory effects. Isoform competition Beyond individual PTM states, relative activity levels among FOXO isoforms constitute a second cell fate regulation layer (Table 3). The four mammalian FOXO proteins show partially overlapping but distinct target gene repertoires, creating functional competition opportunities influencing death versus survival outcomes. FOXO3 dominance generally favors protective responses. FOXO3 exhibits the broadest antioxidant and autophagy gene target repertoire, and its activation, particularly when deacetylated, efficiently suppresses oxidative damage and maintains proteostasis [56]. However, FOXO3 also carries the strongest pro-apoptotic potential among FOXO isoforms, with particularly potent Bim and FasL induction capacity [82,189]. This bifunctional intensity means FOXO3 dominance benefits only when PTM state favors deacetylation; JNK-phosphorylated FOXO3 drives rapid, robust apoptosis [102,185,190]. FOXO1 dominance shows context-dependent effects. In metabolic stress, FOXO1-driven gluconeogenic and lipolytic programs provide essential substrate support, but sustained FOXO1 activation promotes cell cycle re-entry and apoptosis through p21 and p27 upregulation [35,110,191]. FOXO1 pro-apoptotic potential is particularly prominent in high-metabolic-activity neurons, where energy crisis triggers FOXO1-mediated Bim expression and mitochondrial outer membrane permeabilization [192]. FOXO4 emergence marks cellular senescence and senescence-associated secretory phenotype. FOXO4 expression increases with cellular age and stress accumulation, and its distinctive N-terminal MDM2-binding motif facilitates p53-dependent senescence programs [193]. Unlike FOXO1 and FOXO3, FOXO4 shows relatively weak direct apoptotic induction but promotes paracrine inflammation through SASP factor secretion. In microglia and vascular cells, FOXO4-driven senescence contributes to neuroinflammatory amplification and blood-brain barrier compromise [141,193]. The relative balance between deacetylated, nuclear-retained FOXO3 and phosphorylated, nuclear-excluded FOXO1 correlates with cell fate outcomes, with FOXO3 dominance associated with stress resistance and FOXO1 dominance with apoptosis susceptibility. Elevated FOXO4 marks a distinct pathological state characterized by senescence-associated dysfunction through its p53-dependent maintenance of the senescent cell survival program. Experimental validation of isoform activity ratios as predictive biomarkers requires quantitative single-cell analysis of post-translationally modified protein states. Irreversible commitment points Final stage four program execution involves FOXO-mediated activation of conserved cell death machinery, with distinctive features varying among neuronal populations and stress modalities. This population specificity explains selective vulnerability patterns characteristic of different NDDs (Table 2/3). Mitochondrial apoptosis represents the canonical execution pathway. FOXO1 and FOXO3 transcriptionally upregulate Bim, a BH3-only protein antagonizing anti-apoptotic Bcl-2 and activating Bax/Bak-mediated mitochondrial outer membrane permeabilization. Bim specifically antagonizes Bcl-2 to trigger mitochondrial outer membrane permeabilization [194,195]. Concurrently, FOXO proteins suppress Bcl-xL expression, reducing Cyt C release and caspase cascade activation thresholds [196,197]. The Fas death receptor pathway provides parallel execution capacity. FOXO3-driven FasL expression engages Fas receptor on the same or adjacent cells, activating extrinsic apoptosis through caspase-8 [8,10]. This pathway is particularly prominent in inflammatory contexts where FasL-Fas signaling amplifies death signals across neuronal populations. cell-type-specific execution signatures determine disease phenotypes: Substantia nigra dopaminergic neurons exhibit high intrinsic oxidative metabolism that creates dependence on FOXO3-mediated antioxidant defense as detailed in Section 4.1.2; failure of this protective mechanism triggers rapid FOXO3-driven mitochondrial apoptosis. This FOXO3-dependency underlies selective vulnerability in PD [198]. Spinal cord and cortex motor neurons possess large axonal arbors and high metabolic demand that creates dependence on FOXO1-mediated EAAT2 regulation (in Section 4.2.2); failure triggers excitotoxic-FOXO1 amplification. This FOXO1-glutamate coupling underlies vulnerability in ALS [18,53,54]. Caudate and putamen striatal medium spiny neurons show dual dependence on FOXO1-PGC-1α metabolic support (Section 4.1.1) and FOXO3-autophagy quality control (Section 4.3.1); failure triggers coordinated metabolic collapse. This FOXO1/3 co-dependency underlies vulnerability in HD. Metabolic memory and disease predisposition extend Tier IV mechanism relevance beyond acute cell death. Epigenetic modifications established during stress responses, including DNA methylation patterns, histone acetylation marks, and non-coding RNA expression, create heritable states influencing subsequent stress responses and disease susceptibility. FOXO1-mediated PGC-1α promoter hypermethylation (Section 4.3.3), for example, permanently impairs mitochondrial biogenesis capacity, predisposing to earlier stage four entry in future stress episodes. This tier-disease correspondence provides a mechanistic scaffold for the disease-specific discussions in Section 5, where individual FOXO isoform functions are contextualized within specific pathological settings. FOXO in neurodegenerative diseases: disease-specific manifestations of tiered stress responses The hierarchical FOXO stress response Tier I - IV outlined in Section 4 manifests differently across NDDs depending on the predominant cellular compartment affected, the specific FOXO isoform repertoire in vulnerable populations, and the temporal dynamics of disease progression. This section examines how the universal mechanisms of each tier manifest in AD, PD, ALS, HD, MS, and FTD. FOXO and Alzheimer's disease In the context of AD, microglial activation is triggered by factors such as Aβ accumulation and tau hyperphosphorylation. This process is modulated by alterations in FOXO1 functionality within neurons, which in turn affect both the magnitude of microglial activation and their subsequent behavior. When FOXO1 fails to effectively manage excessive microglial activation, these cells release substantial quantities of proinflammatory mediators, further intensifying neuroinflammation [44,45,49]. Microglia also require neuronal FOXO1 signaling to phagocytose Aβ and tau proteins [120,126] (in Section 4.2.1). Disrupting this interaction impairs clearance, accelerates protein accumulation, and drives AD progression. In recent years, the functions of FOXO proteins in AD have been recognized to exhibit remarkable cell-type specificity and disease-stage dependency. In preclinical AD/mild cognitive impairment, low-level Aβ-induced mitochondrial O2▪-/H2O2 directly oxidizes and inhibits protein phosphatase 1 (PP1) and calcineurin, leading to sustained CDK5 activation. Activated CDK5 phosphorylates FOXO3 at Ser294, promoting its nuclear translocation [56]. Within the nucleus, SIRT1-mediated deacetylation of FOXO3, upregulating antioxidant enzyme expression and reducing ROS levels (see Section 4.1.2) [23,66]. Studies have demonstrated that moderate activation of FOXO3 can attenuate AβO–induced OS and maintain synaptic functional integrity. At this stage, FOXO1 exerts protective control over Aβ generation by suppressing its production detailed mechanistically in Section 5.1.1. Additionally, SIRT1-FOXO1 synergy enhances autophagy gene expression (Section 4.1.2), promoting AβO clearance. However, as the disease progresses to the moderate-to-severe dementia stage, persistent OS and chronic inflammation induce an exhaustive transformation in FOXO functionality. Chronically activated FOXO3 gradually shifts toward pro-apoptotic pathways, inducing neuronal apoptosis through upregulation of death genes (in Section 4.3). Of particular clinical relevance, FOXO3 activation in the hippocampal region precedes neurodegeneration and plaque formation, suggesting it serves as an early disease driver rather than a passive response [199]. In advanced AD, intensified insulin resistance further compromises FOXO activity, creating a vicious cycle: Aβ accumulation induces insulin resistance, insulin resistance reduces FOXO phosphorylation, leading to excessive FOXO activation, which in turn promotes GSK-3β–mediated tau hyperphosphorylation and neuronal death [83,200,201]. Specific regulation of FOXO in Aβ pathology FOXO1, as an essential member of the FOXO family, orchestrates a complex interaction network with Aβ that is central to AD pathology, operating via transcriptional control, signaling pathway interactions, and epigenetic modifications. Under normal physiological conditions, FOXO1 inhibits BACE1 transcription by directly binding to the FRE in the BACE1 gene promoter region, thereby reducing Aβ generation. Furthermore, FOXO1 promotes autophagy both directly and indirectly by enhancing the deacetylase activity of SIRT1. This SIRT1 activation, in turn, upregulates genes that facilitate autophagic clearance of Aβ [202,203]. Complementing this pathway, FOXO1 upregulates antioxidant enzymes and collaborates with NRF2 to strengthen cellular defense against OS, thereby mitigating neuronal damage [204,205]. In AD, persistent Aβ-induced mitochondrial dysfunction elevates O2▪-/H2O2 levels, activating JNK to phosphorylate FOXO1. Hyperphosphorylated FOXO1 detaches from the BACE1 promoter [206], derepressing Aβ production; concurrently, it upregulates GSK-3β, promoting tau hyperphosphorylation—creating a positive feedback loop of oxidative stress and protein aggregation [145]. Moreover, FOXO1 plays a pro-inflammatory role by activating the NLRP3 inflammasome, which releases inflammatory mediators, impairs microglial Aβ clearance, and increases the expression of pro-apoptotic genes such as Bim, leading to neuronal cell death [82,196] and exacerbating Aβ-related damage [207,208]. Concurrently, Aβ-induced oxidative stress disrupts IGF-1/AKT signaling, reducing inhibitory phosphorylation and driving pathological FOXO1 nuclear accumulation (Table 1). Concurrently, altered HDAC2/SIRT1 balance shifts FOXO1 acetylation status, tipping the equilibrium from neuroprotection toward pro-apoptotic and pro-inflammatory outputs (Table 4, Fig. 7). FOXO1-centered signaling network in Alzheimer's disease pathogenesis. This schematic depicts the molecular transitions of FOXO1 from a physiologically regulated state to a pathologically hyperactivated state in AD, organized into three functional zones. Left zone — Physiological state (cytoplasmic retention): Under normal metabolic conditions, insulin/IGF-1 signaling activates PI3K/AKT, which phosphorylates FOXO1 at multiple conserved sites (Thr24, Ser256, Ser319 in human FOXO1). Phosphorylated FOXO1 binds 14-3-3 proteins and is retained in the cytoplasm, limiting transcriptional activity. Acetylation by CBP/p300 further suppresses DNA binding. In this state, FOXO1 minimally influences BACE1 transcription, maintaining low amyloid-beta (Aβ) production. Center zone — Pathological activation (nuclear translocation): In AD, Aβ accumulation and mitochondrial oxidative stress (OS) suppress PI3K/AKT activity while activating stress kinases (JNK, p38 MAPK). Reduced AKT-mediated phosphorylation and SIRT1-mediated deacetylation permit FOXO1 nuclear translocation. Nuclear FOXO1 drives a pathogenic transcriptional program: (i) Aβ amplification loop: derepression of BACE1 promoter increases Aβ production, which further suppresses PI3K/AKT in a positive feedback cycle; (ii) Apoptotic priming: induction of pro-apoptotic effectors (BIM, PUMA, p53), initiating mitochondrial outer membrane permeabilization and caspase-dependent neuronal death; and (iii) Lysosomal dysfunction: altered lysosomal acidification impairs Aβ clearance. Right zone — Microglial neuroinflammation: Aβ oligomers activate microglial NLRP3 inflammasomes, triggering caspase-1 activation and release of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) that exacerbate neuronal stress and further activate neuronal FOXO1. Counter-regulatory switches: HDAC2-mediated FOXO1 repression and SIRT1-mediated deacetylation serve as critical modulators determining the balance between neurodegeneration and cellular adaptation. Abbreviations: BACE1, β-site APP cleaving enzyme 1; CBP, CREB-binding protein; HDAC2, histone deacetylase 2; IGF-1, insulin-like growth factor-1; IL-1β, interleukin-1β; NLRP3, NLR family pyrin domain containing 3; TNF-α, tumor necrosis factor alpha. The functional heterogeneity of FOXO proteins across different cell types exerts profound influences on AD pathogenesis. In hippocampal neurons, the unique role of FOXO6 has garnered increasing attention [118]. Unlike other FOXO members, FOXO6 lacks a nuclear export signal, that renders it acutely responsive to synaptic activity–dependent calcium influx and inflammatory signals. FOXO6 influences memory formation through regulating the expression of synaptic plasticity–related genes; its deficiency leads to cognitive impairment, whereas excessive FOXO6 activation disrupts long-term potentiation via inflammatory mediators such as IL-1β [38]. In cortical neurons, FOXO1 primarily regulates metabolic homeostasis and tau phosphorylation status, with its functional dysfunction closely associated with tau pathology spread observed in advanced AD [42,165,209]. Breakthrough point in recent AD research. A 2024 study confirmed that astrocyte-specific FOXO3 deficiency leads to lipid metabolism disorders, compromised Aβ clearance, and exacerbated synaptic loss. FOXO3 influences microglial recruitment to Aβ plaques through regulating apolipoprotein E (APOE) expression and cholesterol metabolism [210,211]. This discovery reveals the bridging role of FOXO3 in neuro-glial interactions, suggesting that previous research focusing solely on neuronal FOXO functions may have underestimated the therapeutic value of astrocytic FOXO3. Conversely, FOXO1 in microglia primarily regulates M1/M2 polarization states: moderate activation promotes M2-type anti-inflammatory polarization and Aβ phagocytosis, whereas excessive activation drives M1-type pro-inflammatory responses, releasing cytokines such as IL-1β and TNF-α and intensifying neuroinflammation [128,[212], [213], [214]]. Human studies increasingly validate FOXO dysregulation in AD pathogenesis. Postmortem analyses reveal elevated nuclear FOXO3 in AD hippocampus and cortex, correlating with DNA damage responses and reactive astrogliosis rather than solely tangle burden [10]. Genetically, FOXO3 longevity-associated variants are linked to delayed cognitive decline and neuroprotective resilience, while emerging peripheral expression profiles show biomarker potential pending large-scale validation [215,216]. Clinically, therapeutic modulation must be stage-specific: early intervention may leverage SIRT1 activators to restore FOXO-mediated autophagy and antioxidant defense [31], whereas advanced stages likely require targeted inhibition of pro-apoptotic FOXO signaling or cell-type–specific delivery to avoid exacerbating neurodegeneration [41,120]. FOXO and tau hyperphosphorylation FOXO1 exhibits stage-dependent regulation of tau phosphorylation: early adaptive PP2A upregulation and GSK-3β inhibition transition to maladaptive GSK-3β transcriptional activation under chronic inflammation [41,146,217]. This disease-stage-dependent functional switch and its downstream kinase targets are stratified in Table 2. The presence of AβOs induces OS, which activates the JNK/p38 MAPK pathway, resulting in the phosphorylation of FOXO1 and its subsequent translocation into the nucleus. Increased nuclear FOXO1 activity elevates GSK-3β levels, impairs the effectiveness of the PP2A catalytic subunit, and reduces tau dephosphorylation. It also enhances Bim expression, further exacerbating tau phosphorylation [114,218,219]. In parallel, FOXO1 regulates peripheral metabolic genes such as PDK4, which may indirectly modulate neuronal glucose utilization [220,221]. In the context of AD, impaired insulin/IGF-1 signaling reduces AKT-mediated inhibitory phosphorylation of both FOXO1 and GSK-3β, leading to concurrent nuclear accumulation of FOXO1 and activation of GSK-3β [222,223]. Acute FOXO1 activation may reduce tau phosphorylation by enhancing GSK-3β inhibition [146]. Conversely, chronic metabolic stress and oxidative damage disrupt this balance. This disruption promotes tau hyperphosphorylation, cytoskeletal damage, and neuronal loss [224,225]. These findings highlight the context-dependent roles of FOXO1 in AD pathogenesis and suggest that therapeutic modulation of FOXO1 activity requires careful consideration of disease stage and cellular environment. Members of the FOXO family exhibit context-dependent roles in tau-related pathology. In neurons, FOXO3 activation generally promotes autophagy/mitophagy pathways that facilitate clearance of phosphorylated tau, as evidenced by reduced FoxO3a levels correlating with increased tau phosphorylation in ApoE4 carriers [226,227]. The relationship between FOXO3 and GSK-3β appears complex: while protein-protein interactions have been reported [228], FOXO3 does not appear to directly enhance GSK-3β transcription to promote tau phosphorylation. Regarding PP2A, current evidence indicates that PP2A activates FOXO3a via dephosphorylation [217,229], suggesting coordinated rather than antagonistic regulation of tau dephosphorylation. Genetic studies associate FOXO3 longevity variants with stress resistance and proteostasis pathways [227,230], though direct mechanistic links to tau pathology in AD require further validation. Roles for FOXO4 and FOXO6 in tau homeostasis remain less defined; while FOXO6 regulates synaptic plasticity genes in the hippocampus [118], its involvement in metabolic regulation of tau clearance is currently hypothetical. These findings underscore the need for cell-type-specific and disease stage-specific analyses of FOXO functions in AD. CSF proteomic analyses from AD cohorts reveal a strong correlation between phosphorylated FOXO1 and both total tau and p-tau concentrations. A study of familial AD carriers found that the expression profile of FOXO3 target genes changes significantly years before symptom onset symptom onset, suggesting that FOXO dysfunction may represent an early molecular event in tau pathology [176,231]. Furthermore, genome-wide association studies (GWAS) have identified the FOXO3 locus as associated with tau deposition burden, further supporting its role in AD genetic susceptibility [215]. FOXO and Parkinson's disease (PD) Pathological mechanisms and molecular crosstalk in PD PD is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, with α-syn aggregation forming Lewy bodies as its pathological hallmark. Research on FOXO family proteins in PD has revealed unique vulnerability mechanisms of dopaminergic neurons and the central role of mitochondrial quality control [42]. Dopaminergic neurons are uniquely vulnerable to oxidative stress due to dopamine metabolism generates H2O2 and 6-hydroxydopamine and ETC Complex I deficiency leaks O2▪-. These ROS activate FOXO3: mild levels drive SIRT1-deacetylated FOXO3 to upregulate SOD2/CAT for survival, but chronic accumulation triggers JNK-phosphorylated FOXO3 to induce Bim/FasL, causing apoptosis [[232], [233], [234]]. Within this context, FOXO3 activity critically influences neuronal fate: viral-mediated constitutive activation of FOXO3 induces apoptosis in nigral dopaminergic neurons, while appropriate FOXO3 signaling may support stress resistance [152,235]. The interaction between α-synuclein and FOXO transcription factors appears context-dependent; physiological FOXO1/3 activation may enhance autophagic clearance of misfolded proteins [236], whereas pathological α-synuclein aggregation can induce mitochondrial ROS that further modulates FOXO activity. Notably, recent work by Na et al. (2024) demonstrated that α-synuclein preformed fibrils induce mitochondrial ROS in BV-2 microglial cells, while FOXO1 activation attenuates this oxidative damage by upregulating antioxidant genes [15]. These findings suggest that the protective role of FOXO1 in neuroinflammation regulation may indeed be underappreciated, though the precise balance between protective and detrimental FOXO signaling in Parkinson's disease pathogenesis requires further investigation. FOXO1 suppresses α-syn production through two epigenetic mechanisms. Under basal conditions, FOXO1 directly binds the forkhead response element (FRE) within the SNCA promoter, suppressing basal transcription [172]. Upon OS, FOXO1 undergoes dephosphorylation and nuclear translocation, where it recruits HDAC1 to the SNCA promoter; this reduces H3K27 acetylation, induces chromatin condensation, and reinforces epigenetic silencing [31,237]. Critically, this regulatory circuit exhibits negative feedback characteristics: mild α-syn aggregation can further activate FOXO1, thereby amplifying its own transcriptional repression (Fig. 8, orange pathway). Integrated neuroprotective mechanisms mediated by FOXO transcription factors in Parkinson's disease. This diagram illustrates the dual regulatory roles of FOXO1 and FOXO3 in neuronal survival and death pathways in dopaminergic neurons, organized into four distinct signaling modules. Module 1 (far left, orange pathway) —Under basal conditions, FOXO1 binds the forkhead response element (FRE) within the SNCA promoter, suppressing α-synuclein (α-syn) transcription. Upon oxidative stress (OS), FOXO1 undergoes AKT-mediated dephosphorylation and nuclear translocation, where it recruits HDAC1 to the SNCA promoter. HDAC1-mediated H3K27 deacetylation induces chromatin condensation, reinforcing epigenetic silencing of α-syn and reducing protein aggregation. Module 2 (center-left, pink pathway) —Natural compounds (quercetin, curcumin) and caloric restriction mimetics activate the AMPK-SIRT1 signaling cascade. AMPK phosphorylates and activates FOXO1, while SIRT1 deacetylates FOXO1, enhancing its transcriptional stability and α-syn suppressive activity. Module 3 (center-right, blue pathway) — Exercise-induced SIRT1-FOXO1/PINK1-Parkin mitophagy: Physical exercise elevates muscle-derived irisin and activates hypothalamic SIRT1-FOXO1 signaling. FOXO1 upregulates PINK1 expression, priming mitochondria for quality control. PINK1 accumulation on damaged mitochondria recruits Parkin E3 ubiquitin ligase, initiating mitophagy and clearing damaged, ROS-generating organelles. This exercise-responsive pathway facilitates α-syn aggregate clearance through improved mitochondrial function. Module 4 (far right, green pathway) —Toxin exposure or mutations activate JNK/p38 MAPK stress kinases. JNK phosphorylates FOXO3, promoting nuclear retention and disrupting SIRT1 binding. Nuclear FOXO3 transcriptionally upregulates pro-apoptotic factors (Bim, FasL) while concurrently inhibiting anti-apoptotic Bcl2 and mitophagy-related PINK1. This shifts the cellular balance toward mitochondrial apoptosis, dopaminergic neuron death, and disease progression. Abbreviations: AMPK, AMP-activated protein kinase; FasL, Fas ligand; FRE, forkhead response element; H3K27, histone H3 lysine 27; PINK1, PTEN-induced kinase 1; SNCA, synuclein alpha gene. Nevertheless, in the advanced stages of the disease, the effectiveness of FOXO1 decreases, disrupting the regulation of SNCA expression. A study by Rey et al. confirmed that diminished levels of FOXO1 corresponded with increased SNCA mRNA and increased α-syn aggregates, highlighting the critical role of FOXO1 in maintaining protein homeostasis [172,238]. Recent studies have shown that natural compounds, such as quercetin and curcumin, may stimulate the AMPK-SIRT1 signaling pathway, thereby enhancing both the stability and transcriptional activity of FOXO1. In MPTP-induced PD models, quercetin has been shown to increase the levels of FOXO1 in the nucleus while reducing α-syn phosphorylation [31,239] (Fig. 8, pink pathway). Additionally, physical exercise has been found to activate the SIRT1-FOXO1/PINK1-Parkin pathway, with regular physical activity promoting mitophagy and facilitating the clearance of α-syn aggregates [77] (Fig. 8, blue pathway). Mitochondrial dysfunction represents a core pathological mechanism in PD. The PINK1-Parkin pathway serves as a key regulator of mitophagy, while the Sir2/FOXO axis can exert protective effects independently of Parkin [240]. PGC-1α drives mitochondrial biogenesis as a master regulator. In contrast, FOXO1 suppresses this pathway in most peripheral tissues [26]. Future studies must validate its specific role in dopaminergic neurons. Mechanistically, pathological α-synuclein aggregation translocates to the nucleus and directly represses PGC-1α transcription, contributing to complex I deficiency [241]. These findings highlight the complexity of FOXO-mitochondria interactions in PD pathogenesis. The LRRK2-FOXO axis represents a critical mechanism in PD pathogenesis. The most common PD causative gene, LRRK2, phosphorylates and activates FOXO proteins, promoting dopaminergic neurodegeneration, a process further amplified by NO-cGMP signaling via cGKII, forming a positive feedback loop [242,243]. Notably, phosphorylation-resistant FOXO mutants (S259A) block this toxic cascade, offering gene therapy prospects for hereditary PD. In advanced PD, chronic OS triggers JNK-mediated FOXO3 phosphorylation, driving a stress-dependent functional switch from antioxidant defense to apoptosis execution via Bim/FasL induction (Table 2, Fig. 8, green pathway). Clinical evidence and translational strategies Postmortem analyses of human PD brain tissue reveal altered FOXO expression patterns that correlate with disease pathology. Transcriptomic profiling of PD prefrontal cortex demonstrates significant dysregulation of FOXO1 and its downstream target genes, implicating disrupted transcriptional networks in vulnerable neuronal populations [244]. While nuclear FOXO3 accumulation has been observed in stress-vulnerable regions, the precise spatiotemporal dynamics of FOXO1 in α-synucleinopathy remain under active investigation. Emerging human biomarker studies are beginning to bridge this translational gap; for instance, peripheral blood microRNA profiles that regulate FOXO signaling show promise as early diagnostic indicators and disease progression markers [16,245]. Genetically, FOXO3 variants are robustly associated with human longevity and neuroprotection [215,216], and accumulating cohort data suggest that preserved FOXO pathway integrity may modulate PD clinical trajectories, though large-scale GWAS specifically linking FOXO polymorphisms to PD age of onset are still evolving. However, direct in vivo validation of FOXO1-mediated SNCA repression in human brain remains limited. The clinical translation of pharmacological FOXO1 activation is further complicated by its essential systemic metabolic roles, necessitating careful risk-benefit evaluation and cell-type–specific delivery strategies. Therapeutic strategies targeting FOXO in PD now span pharmacological and lifestyle interventions. Regular exercise activates the SIRT1-FOXO1/PINK1-Parkin axis to enhance mitophagy and α-syn clearance, as validated in MPTP-induced models [77,98,149]. Natural compounds including quercetin and curcumin similarly bolster FOXO1 stability and transcriptional activity via AMPK-SIRT1 signaling, thereby reducing α-syn phosphorylation [173,239]. Caution is warranted, however, as excessive FOXO3 activation in advanced PD—where persistent OS prevails—may convert its function from antioxidant protection to pro-apoptotic signaling, underscoring the need for precise temporal and dosing control. FOXO and amyotrophic lateral sclerosis (ALS) In ALS, oxidative stress—often associated with SOD1 mutations—activates FOXO1, contributing to motor neuron death and glial dysfunction. The SOD1-G93A mutation leads to a buildup of mitochondrial superoxide anion (O2▪-) and hydrogen peroxide (H2O2), which in turn activates the phosphatase PP2A; this activity supports the dephosphorylation and nuclear translocation of FOXO1 [161]. Once it enters the nucleus, FOXO1 interacts with the promoters of pro-apoptotic genes, subsequently initiating apoptotic pathways, while also increasing the expression of VDAC1, a protein located in the outer mitochondrial membrane [246]. This alteration disrupts calcium homeostasis, activates calcium-dependent ribonucleases, and accelerates neuronal death. This pathway has been validated in the SOD1-G93A mouse model [247,248]. TDP-43 proteinopathy, the pathological hallmark of most ALS cases, engages in a complex bidirectional relationship with FOXO3. Under pathological conditions, FOXO3 downregulates the nuclear import receptor Importin-α1, disrupting TDP-43 nucleocytoplasmic transport and promoting its cytoplasmic aggregation and inclusion formation [249,250]. Aggregated TDP-43 impairs axonal transport of target mRNA granules, potentially compromising local stress responses in distal neuronal compartments [251,252]. Under proteotoxic stress, cytoplasmic TDP-43 competes with FOXO transcription factors for binding to 14-3-3 proteins, promoting FOXO nuclear translocation and activation of stress-responsive genes [175]. While Importin-α1/β facilitates TDP-43 nuclear import and may prevent its cytoplasmic aggregation [249,253], a direct FOXO3-Importin-α1-TDP-43 axis has not been experimentally established. These findings highlight the complexity of TDP-43-FOXO crosstalk in ALS-FTD pathogenesis and suggest that therapeutic targeting of this interaction requires careful consideration of cellular context and disease stage. The 2024 study published in Acta Neuropathologica fundamentally transformed our understanding of ALS. Zufiría et al. discovered FOXO1-mediated intrinsic dysfunction in skeletal muscle of ALS patients, with these abnormalities appearing even before motor neuron degeneration [18]. Specific mechanisms include: TDP-43 or FUS knockdown leads to glucose oxidation defects and myogenesis impairment in myoblasts [254,255]; FOXO1 serves as a key mediator of these metabolic and functional characteristics; and FOXO1 inhibition can improve myogenesis defects in genetically modified and primary ALS myoblasts [256,257]. In Drosophila models, muscle-specific TDP-43 or FUS knockdown causes neuromuscular junction dysfunction, while foxo inhibition can partially rescue these phenotypes [255,258]. This suggests that skeletal muscle may serve as a complementary therapeutic target tissue in ALS, and pharmacological management targeting muscle FOXO1 may improve intrinsic muscle abnormalities, thereby delaying disease progression. This "non-cell-autonomous" mechanism opens new directions for ALS therapeutic strategies. In contrast, the aggregation of TDP-43 in abnormal forms disrupts RNA metabolism, leading to impairments in axonal transport [251]. Compounding neuronal vulnerability, ALS neurotoxicity is exacerbated by disrupted neuro-astrocytic metabolic coupling. As detailed in Section 4.2.2, physiological FOXO signaling contributes to cellular stress responses, while in ALS, dysregulated FOXO1 activity may indirectly impact glutamate homeostasis [259]. In SOD1-G93A models, reduced expression of the astrocytic glutamate transporter GLT-1/EAAT2 has been consistently observed, contributing to extracellular glutamate accumulation [260,261]. Human studies report elevated CSF glutamate levels in subsets of ALS patients, suggesting impaired glutamate clearance mechanisms [262]. Importantly, metabolic disturbances in both neurons and glia precede overt motor neuron degeneration [18], indicating that early targeting of glutamate homeostasis pathways. Including potential modulation of FOXO-related signaling, represents a promising early-stage therapeutic strategy to mitigate excitotoxicity while preserving downstream neuroprotection. These findings carry important clinical translation implications. First, serum FOXO3 levels may serve as biomarkers for early ALS diagnosis and progression monitoring [161,263]. Second, interventions targeting skeletal muscle FOXO1 may provide "dual benefits"—improving muscle function while indirectly protecting motor neurons through reducing peripheral factor release [255]. Finally, the development of FOXO modulators must consider disease stage: early disease may benefit from FOXO3 activation to enhance antioxidant defense, whereas advanced disease may require FOXO1 inhibition to attenuate muscle atrophy and glutamate toxicity [264]. FOXO and Huntington's disease (HD) As HD progresses, dysregulation of PI3K/AKT signaling has been observed in experimental models, which may contribute to altered FOXO subcellular localization and transcriptional activity [265]. FOXO3 levels are elevated in both HD patient caudate nuclei and R6/2 mouse striatum due to an overactivated positive autoregulatory loop, wherein FOXO3 binds to its own promoter to amplify transcription [27]. FOXO transcription factors can regulate both cytoprotective targets and pro-apoptotic genes depending on cellular context [90]; in HD neural cells, FOXO3 target reprogramming has been documented, though the temporal relationship between mHTT burden and transcriptional output shifts requires further systematic investigation [19]. mHTT may indirectly modulate FOXO activity through dysregulation of upstream kinases or sequestration of shared transcriptional cofactors, though direct physical interactions between mHTT and FOXO proteins have not been demonstrated [266]. In early HD, the XBP1–FOXO1 axis mitigates ER stress and accelerates mHTT clearance via macroautophagy upregulation, while the SIRT1–FOXO3 axis sustains antioxidant defense and motor function [90]. The NAD+-dependent deacetylation dynamics and stage-specific efficacy limits of these axes are detailed in Table 1, Table 4. Striatal MSN vulnerability is tightly coupled to FOXO1-driven metabolic collapse. mHTT severs the FOXO1–PGC-1α interaction, suppressing mitochondrial biogenesis and downregulating fatty acid oxidation genes [[267], [268], [269]]. Longitudinal 7-T magnetic resonance spectroscopy (7T-MRS) imaging in premanifest HD carriers reveals that striatal metabolic disturbances, including lactate accumulation and N-acetylaspartate depletion, emerge years before clinical diagnosis, correlating with disease burden scores (CAP = age × [CAG−33.66]) [270]. While direct in vivo measurement of FOXO1-PGC-1α pathway activity remains challenging, postmortem and preclinical studies demonstrate that mHTT-mediated repression of PGC-1α transcription contributes to early mitochondrial dysfunction and impaired fatty acid oxidation [271]. The temporal relationship between FOXO pathway dysregulation and detectable metabolic changes likely varies by individual CAG repeat length, age, and genetic modifiers. Compounding transcriptional dysregulation, chronic FOXO overactivation establishes a "pathological memory" via autoregulatory loops, reinforcing maladaptive gene expression. Emerging evidence implicates FOXO4-mediated cellular senescence in HD progression; FOXO4-p53 interactions sustain senescent glial survival and SASP-driven neuroinflammation [19,272]. Although HD-specific validation of senolytics (e.g., FOXO4-DRI) is pending, preclinical models demonstrate their potential to clear senescent cells, dampen inflammation, and restore cognitive function, positioning the FOXO4-senescence axis as a promising therapeutic frontier [193]. FOXO and Multiple sclerosis (MS) FOXO family members, particularly FOXO1 and FOXO3, contribute to multiple sclerosis (MS) pathogenesis through multifaceted regulation of immune cell differentiation and inflammatory mediator production. Candidate gene studies suggest that specific haplotypes in FOXO1 (e.g., GGTT) and variants in FOXO3 may associate with increased susceptibility to relapsing-remitting MS, potentially via modulation of regulatory T cell (Treg) functionality [177,273]. Mechanistic studies using experimental autoimmune encephalomyelitis (EAE) models demonstrate that Foxo1 signaling is essential for maintaining the Th17/Treg equilibrium: Foxo1 directly represses Rorc (encoding the Th17 master regulator RORγt) and Ifng transcription, thereby constraining pathogenic Th17 differentiation while preserving Treg suppressive capacity [136,274,275]. Regarding post-translational regulation, SIRT1-mediated deacetylation of FOXO proteins modulates their subcellular localization and target gene selectivity in a context-dependent manner. Under homeostatic conditions, SIRT1-FOXO interactions promote antioxidant and pro-survival transcriptional programs; however, chronic inflammatory stimuli may disrupt this balance, leading to aberrant NF-κB activation and sustained release of pro-inflammatory cytokines that amplify central nervous system (CNS) inflammation [66,276]. Of translational significance, pharmacological SIRT1 activation suppresses microglial NF-κB signaling and ameliorates neuroinflammation in preclinical models, underscoring the therapeutic potential of this axis [277]. During the progressive disease phase, mitochondrial stress induces FOXO3 nuclear translocation, activating pro-apoptotic genes, leading to oligodendrocyte and neuronal death. When EAE models simulate progressive MS, early mitochondrial DNA damage and cristae structural alterations are observed in spinal cord axons, accompanied by upregulation of mitochondrial biogenesis–related genes such as PGC-1α and FOXO [278]. However, as ROS accumulate, this compensatory mechanism gradually weakens. Reduced AKT activity decreases the phosphorylation that normally inhibits FOXO, while dysfunction in the ubiquitin-proteasome system increases FOXO protein stability. Abnormal accumulation of FOXO further suppresses mTOR signaling, impedes autophagic processes, and accelerates neurodegeneration through accumulation of damaged mitochondria and protein aggregates [52,179]. Various microRNAs (miRNAs) play crucial roles in MS pathology, regulating FOXO and its related pathways. For example, miR-155-5p, which is notably increased in MS lesions, acts directly on FOXO3 and CDKN1B to inhibit their functions, thereby eliminating restrictions on the cell cycle. This action results in the abnormal proliferation of oligodendrocyte precursor cells, which impairs myelin repair [279]. Studies indicate a substantial reduction in let-7f-5p levels within the plasma of MS patients, leading to increased expression of its target, FOXO1. This upregulation initiates the FOXO signaling pathway, which in turn promotes neuronal cell death [184,280]. In a parallel regulatory axis, OS-induced upregulation of miR-200a indirectly facilitates FOXO1 acetylation by suppressing SIRT1, thereby promoting p53-mediated apoptotic processes within the CNS [173]. The dysregulation of these miRNAs establishes distinctive regulatory networks that amplify the impact of the FOXO pathway on neurodegenerative processes in MS. Analysis of postmortem brain tissue from individuals with multiple sclerosis demonstrates that nuclear accumulation of FOXO3 in oligodendrocyte precursor cells (OPCs) within chronic white matter lesions correlates with impaired myelin gene expression, suggesting a role in remyelination failure [281]. Candidate gene studies have reported associations between FOXO1 variants and relapsing-remitting MS susceptibility, though these findings require validation in larger, independent cohorts [177]. Mechanistic studies using experimental models indicate that persistent activation of the TLR4/AKT/FOXO3 axis in OPCs disrupts myelin gene transcription through dysregulated interactions with chromatin-remodeling complexes and lineage-determining transcription factors such as Olig2 [281]. While large-scale genome-wide association studies have not identified FOXO family members as genome-wide significant risk loci for MS [273], pathway-level analyses suggest that AKT-FOXO signaling may be enriched among immune-relevant genetic risk factors, warranting further investigation into its contribution to disease heterogeneity and treatment response. FOXO and frontotemporal dementia (FTD) In frontotemporal dementia (FTD), emerging mechanistic studies suggest that the RNA-binding protein TDP-43 may modulate cellular protein homeostasis through regulation of FOXO transcription factors. Under physiological conditions, TDP-43 and FOXO proteins competitively bind to 14-3-3 scaffold proteins in the cytoplasm; stress-induced cytoplasmic translocation of TDP-43 can release FOXO factors for nuclear import, where they activate transcription of proteasomal and autophagic genes involved in misfolded protein clearance [175]. However, pathological accumulation of TDP-43— a hallmark of FTLD-TDP—may disrupt this regulatory equilibrium. Preclinical models indicate that persistent TDP-43 aggregation can sequester 14-3-3 proteins, potentially altering FOXO nucleocytoplasmic dynamics and promoting sustained nuclear retention associated with pro-apoptotic transcriptional programs [282]. Concurrently, TDP-43 pathology impairs stress granule dynamics, contributing to chronic proteotoxic stress and neuronal vulnerability [283]. While these mechanistic insights derive primarily from cell culture and invertebrate models, human biomarker studies in FTD remain limited. Plasma extracellular vesicle analyses have identified TDP-43 and tau isoforms as promising diagnostic biomarkers for molecular subtyping of FTD [284], but whether FOXO signaling components in biofluids reflect disease activity or progression requires systematic investigation. Similarly, although postmortem studies confirm TDP-43 inclusion burden in the frontal cortex of FTLD-TDP cases, the spatial and quantitative relationship between TDP-43 pathology and FOXO3 subcellular localization remains to be characterized in human tissue. Future studies integrating single-nucleus transcriptomics, spatial proteomics, and longitudinal biofluid sampling will be essential to validate the translational relevance of the TDP-43–FOXO axis in FTD pathogenesis and therapeutic monitoring. Cross-disease comparison and clinical translation framework Cross-disease comparisons reveal that FOXO isoforms exhibit both conserved stress-response functions and disease-specific adaptations, providing a framework for precision therapeutic design. FOXO1 exemplifies this duality: it suppresses Aβ generation via BACE1 transcriptional repression in early AD [146,206,285], enhances mitophagy to protect dopaminergic neurons in PD [30,77,286], drives skeletal muscle dysfunction as an upstream event in ALS [18], and promotes autophagic clearance of mHTT aggregates in HD [19,90]. These context-dependent roles reflect unique interactions between FOXO signaling and disease-specific pathological proteins (Aβ, α-syn, TDP-43, mHTT). Similarly, FOXO3 displays stage-dependent functional switching across NDDs. Longitudinal human studies show serum FOXO3 levels rise during early disease stages—consistent with adaptive antioxidant responses—but diverge in advanced stages depending on inflammatory status and metabolic reserves [287]. This "double-edged sword" phenotype is universal yet threshold-variable: astrocytic FOXO3 promotes Aβ clearance in AD [198], whereas neuronal FOXO3 activation drives apoptosis in PD substantia nigra [10,288]; motor neurons and skeletal muscle exhibit differential FOXO3 sensitivity in ALS [18,247]; and HD features a FOXO3 autoregulatory positive feedback loop that amplifies pathological memory [27]. Cell-type specificity represents a core translational challenge. FOXO functions may be diametrically opposed across cellular compartments: FOXO1 promotes neuronal apoptosis yet regulates microglial M1/M2 polarization [45,126]; FOXO3 enhances astrocytic Aβ clearance but may drive T-cell autoimmunity in MS [58,59]. Therapeutic strategies must therefore incorporate cell-type–specific promoters and targeted delivery systems to avoid paradoxical outcomes. The inherent context-dependency of FOXO networks necessitates three precision requirements for clinical translation: (i) stage-defined intervention windows guided by biomarkers [289]; (ii) cell-type–selective delivery vehicles to overcome blood-brain barrier constraints [141,290]; and (iii) isoform-selective modulators to minimize systemic metabolic liabilities [35]. Future directions should prioritize senolytic strategies targeting the FOXO4-p53 axis [193] and metabolic reprogramming interventions via the FOXO1-PGC-1α pathway [26,96], both of which hold cross-disease therapeutic potential. Potential therapeutic applications of FOXO in the treatment of NDDs The FOXO transcription factor family represents a pivotal node in the neurodegenerative disease network, integrating pathways such as OS, neuroinflammation, and autophagy (Table 2, Table 3, Table 4, Table 5). Therapeutically, the conserved FHD presents a key target for intervention. For example, FOXO1 enhances antioxidant enzyme expression under OS, whereas FOXO3 inhibits proinflammatory agents through the NF-κB pathway (Table 3). This dual regulatory capacity provides a strategic edge for disease-modifying interventions. Preclinical studies demonstrate that FOXO transcriptional activities can be dynamically regulated through PTMs (Table 1, Section 3) [291]; conversely, OS-induced JNK phosphorylation increases DNA-binding ability. This plasticity establishes foundations for diverse therapeutic strategies: (i) Small-molecule modulators targeting PTMs, such as resveratrol promoting FOXO3 deacetylation [174] and alginate recruiting FOXO1 into TFEB-dependent pathways [292]; (ii) Gene therapy approaches, including adeno-associated virus (AAV)-mediated TREM2 delivery acting through the PI3K/AKT/FOXO3 axis [122] and direct FOXO1 gene editing for mitochondrial rejuvenation [244]; and (iii) Epigenetic interventions, such as CRISPR-dCas9-mediated PGC-1α promoter demethylation restoring FOXO1-dependent mitochondrial biogenesis [26,35]. These strategies leverage distinct FOXO functional roles, enabling development of systemic interventions targeting common neurodegenerative pathways (Table 4). Multitarget regulation of FOXO1 in NDDs and precision intervention strategies FOXO1 emerges as a particularly promising therapeutic target due to its multifaceted regulatory roles. In AD, FOXO1 critically regulates Aβ buildup and tau hyperphosphorylation. The small-molecule inhibitor AS1842856 interferes with FOXO1-BACE1 interaction, reducing Aβ accumulation in APP/PS1 mice [293,294]. SIRT1 activators like resveratrol promote FOXO1 deacetylation, increasing insulin-degrading enzyme and microglial phagocytosis gene TREM2 [49,50]. FOXO1 activation via physalin B diminishes GSK-3β activity, reducing tau expression and phosphorylation [14]; JNK inhibitor SP600125 decreases FOXO1 nuclear translocation, further reducing tau pathology [295]. HDAC inhibitors restore FOXO1 promoter acetylation while downregulating microglial activation markers [296,297]. The allosteric modulator TAK-242 activates TLR4/FOXO1/SOD2, demonstrating intervention effects on both Aβ and tau pathologies [123,298]. In PD, FOXO1 promotes α-syn clearance and mitochondrial stability. The small molecule STF-62247 activates FOXO1-PINK1 pathway, enhancing mitophagy and dopaminergic neuron survival in MPTP models. For LRRK2 mutations, peptide inhibitors disrupt atypical LRRK2-FOXO1 binding, reducing pathological α-syn phosphorylation and improving mitophagy [93,242,243,299,300]. FOXO1-PINK1-Parkin interplay facilitates α-syn ubiquitination and autophagic degradation [73]. Resveratrol-mediated FOXO1 deacetylation (Section 4.1.2) additionally enables PGC-1α collaboration for mitochondrial biogenesis in PD [30,202]. miR-135b steers FOXO1 transcriptional activity toward antioxidant profiles, reducing mitochondrial ROS and NLRP3 inflammasome activation [245,301]. Beyond AD and PD, FOXO1 modulates calcium equilibrium and TDP-43 transport in ALS [302,303]; AS1842856 inhibits FOXO1 nuclear entry, reducing myostatin and improving survival. Antisense oligonucleotides upregulate EAAT2, reducing glutamate excitotoxicity [304]. In HD, puerarin activates PI3K/AKT/FOXO1 increasing BDNF [305]; resveratrol modifies FOXO1 function to decrease mHTT suppression of PGC-1α. GC-1 stimulates FOXO1-PGC-1α pathway, bolstering mitochondrial ATP synthesis [306]. In MS, FOXO1 modulates immune reactions targeting Th17 differentiation while increasing Treg activity [137]; small-molecule inhibitors disrupting FOXO1-RORγt interaction reduce IL-17-positive cells and increase Treg functionality [307]. In FTD, the export inhibitor KPT-330 facilitates TDP-43 nucleocytoplasmic redistribution [308]; small molecules redirect FOXO1 to TDP-43 promoter, inhibiting abnormal transcription [175,220]. Multitarget regulation and synergistic therapeutic networks of other FOXO family isoforms in NDDs Other FOXO members represent promising complementary targets. In AD, FOXO3 AAV vector delivery restores APP promoter association, reducing BACE1 and activating autophagy genes [167,309]. FOXO4 small-molecule inhibitors disrupting p53 interaction reduce neuronal death and Aβ toxicity [193]; FOXO4 shRNA decelerates NFT progression in tau transgenic mice. FOXO6 activates TF/PAR2/AKT signaling elevating IL-1β, disrupting hippocampal synaptic plasticity [116]; AKT activator SC79 reduces FOXO6-induced IL-1β in diabetic brains, improving cognition. In PD, FOXO3 activators increase MnSOD, reducing neuronal death in 6-OHDA models and α-syn aggregates via PINK1/Parkin [310]. FOXO4 inhibitors hinder p53 binding, delaying neuronal aging and mitigating α-syn toxicity [152]. In ALS, FOXO3 overexpression facilitates autophagy and reduces TDP-43 aggregate formation; small-molecule activators promote autophagy through mTOR-FOXO3 signaling [311]. FOXO4 inhibitors disrupt p53/p21, delaying motor neuron aging [193]. FOXO6 activators restore GLUT3, increasing energy metabolism and regulating glutamine synthetase to alleviate glutamate toxicity [312]. In HD, genistein inhibits FOXO3, affecting autophagy gene expression and curtailing mHTT aggregate buildup [313]. AKT inhibitor MK-2206 increases FOXO4 protein, enhancing proteasome function [160]. In MS, SGK2 activator OCS-05 activates FOXO3 governing anti-apoptotic, antioxidant gene expression, protecting neurons and modulating T-cell activation [48]. In FTD, FOXO3-TREM2 interaction reduces inflammatory responses and cognitive deficits [314]. These isoform-specific strategies operate synergistically with FOXO1 pathways, enhancing therapeutic precision through pathogen elimination, cellular aging inhibition, and metabolic balance restoration. Safety assessment of FOXO1-targeted therapies Significant advancements notwithstanding, safety concerns remain prominent. FOXO1's regulatory role within insulin/IGF-1 signaling requires careful systemic toxicity evaluation. Preclinical studies indicate that systemic FOXO1 activation may cause metabolic disturbances: sustained hepatic gluconeogenic gene upregulation leading to excessive glucose output [35,94], exacerbated in high-fat diet models with increased proinflammatory markers and adipose tissue inflammation [291,315]. Hematologic toxicity represents critical safety considerations, particularly for systemic gene delivery. AAV-mediated FOXO1 overexpression in mice reports hematopoietic suppression, reduced bone marrow HSC proliferation, and leukopenia [316], potentially involving p21 and p27 upregulation. FOXO1 effects on vascular endothelial cells may cause coagulopathy; primate studies suggest increased tissue factor pathway inhibitors, diminished platelet aggregation, and prolonged bleeding [317,318]. CNS toxicity primarily indicates neuronal energy metabolism disruption. In PD models, FOXO1 activator STF-62247 enhances mitophagy while reducing striatal ATP, creating autophagy-energy imbalance potentially promoting degeneration [319]. Supraphysiological FOXO1 activation associates with reduced action potential frequency and impaired synaptic function [[320], [321], [322]]. Blood-brain barrier permeability alterations present additional concerns: FOXO1 activation downregulates tight junction proteins, increasing blood-brain barrier (BBB) permeability and immune cell infiltration [141]. FOXO1-driven pericyte apoptosis decreases cerebral microvessel density, compromising cerebral blood flow [142,290]. Toxicological profiles vary by intervention method. Small-molecule modulators show pronounced off-target effects—resveratrol inhibits P450 enzymes, impairing liver function and drug metabolism [323]. FOXO1 inhibitor AS1842856 obstructs PI3K-AKT, potentially impeding neuronal survival [5,324]. Gene therapy encounters immunogenic hurdles: high-dose AAV9 in nonhuman primates triggers T-cell responses, neurotoxicity, elevated CSF IFN-γ, and astrocyte proliferation [175,325,326]. Clinical translation status The four-tier stress-response framework offers a mechanistic lens to reinterpret current clinical development patterns and address persistent translational gaps. While Phase I/II trials increasingly investigate metabolic and neuro-immune modulators that target early adaptive pathways, they rarely incorporate biomarker-driven stratification to distinguish Tier I homeostatic compensation from Tier II intercellular recruitment. In contrast, interventions deployed in moderate-to-advanced populations frequently confront Tier III lysosomal dysfunction and Tier IV apoptotic commitment, where the capacity for pharmacological reversal is inherently limited. Emerging precision medicine paradigms suggest that integrating stage-resolved biomarkers—including CSF post-translational modification profiles, glial activation signatures, and autophagic flux markers—into companion diagnostic workflows could realign trial enrollment with quantifiable pathological thresholds. This biologically stratified approach shifts the focus from uniform dosing to context-aware intervention, potentially improving target engagement rates and reducing the off-pathway toxicities observed in broad-spectrum NDD trials. North American clinical trials registry (2023-2025) (ClinicalTrials.gov) An analysis of the ClinicalTrials.gov registry reveals the current research priorities, with a prominent focus on metabolic and anti-inflammatory interventions. However, the transition from these early-stage investigations to FDA-approved therapies remains a significant hurdle, as illustrated by the limited number of recent approvals directly targeting FOXO-related pathways. NO.DiseaseInterventionsStudy typeKey Clinical InformationPhasesNCT05947396NDDsSMARTO ONERCTPrimary endpoint: Safety and efficacy of flavonoids [327].NANCT05947409SMARTO ONESingle-armPrimary endpoint: Safety and preliminary efficacy [328].NANCT06470061ADRQCRCTCohort size: Not specified; Primary endpoint: Retinal Aβ changes, cognitive decline (MMSE); Dose: 2000 mg curcumin +334 mg resveratrol + 60 mg quercetin daily [329].2NCT05227820NE3107Open-labelCohort size: n = 23; Dose: 20 mg BID for 3 months; Primary endpoints: Cerebral blood flow, functional connectivity, glutathione levels [330].2NCT05603312PDAAV-GADDouble-blind RCTCohort size: n = 44 advanced PD patients; Primary endpoint: Safety, UPDRS motor scores; Delivery: Bilateral STN infusion of AAV2-GAD (1×1012 vg) [331].1/2NCT05894343AAV-GADlong-term follow-upCohort size: Prior trial participants; Primary endpoint: Long-term safety monitoring [332].1/2NCT06339034LithiumRCTPrimary endpoint: Safety and efficacy of lithium in PD; Note: Prior ALS trials showed negative results [333].1/2NCT04687878InsulinRCTPrimary endpoint: Motor and non-motor symptoms; Evidence basis: Meta-analysis shows cognitive improvement in AD/MCI (SMD = 0.22, P < 0.00001); PD pilot study (n = 14) confirmed safety [334].2NCT04251585Novolin RRCTPrimary endpoint: Safety and efficacy; Drug: Regular human insulin via intranasal spray [335].2NCT04167540AAV2-GDNFopen-labelCohort size: n = 12 (6 early-stage, 6 advanced); Primary endpoint: Safety, tolerability; Delivery: Single bilateral putaminal infusion; Completion: Expected 2027 [336].1NCT06099886LithiumRCTSponsor: NIH-funded; Start date: October 2023; Primary endpoint: Safety and tolerability [337].1NCT06469853HDMBF-015RCTPrimary endpoint: Safety, pharmacokinetics, pharmacodynamics [338].2NCT04617847WVE-120101Open-label ExtensionCohort size: Prior trial participants; Primary endpoint: Long-term safety and tolerability [339].1/2NCT05243017rAAV5-miHTTPhase I/IIPrimary endpoint: Safety and efficacy; Delivery: AAV5-miHTT stereotactic intrastriatal injection [340].1/2NCT05032196WVE-003Phase I/IIPrimary endpoint: Safety and efficacy of HTT-targeting ASO [341].1/2NCT04931862ALS/FTDWVE-004Phase I/IIPrimary endpoint: Safety and efficacy; Target: C9orf72 repeat expansion [342].1/2NCT06665165ALSAMX0114Phase IPrimary endpoint: Safety and tolerability; Drug: SOD1-targeting ASO [343].1NCT06100276AMT-162Phase I/IIPrimary endpoint: Safety, tolerability, exploratory efficacy; Route: Intrathecal; Target: SOD1 [344].1/2NCT05633459QRL-201Phase IPrimary endpoint: Safety and tolerability; Drug: STMN2-targeting ASO [345].1NCT04654689resveratrol curcuminPhase IIPrimary endpoint: Safety and efficacy; Intervention: Liposomal polyphenols + G04CB02 [346].2NCT05470478mobile iBCI-Population: Veterans; Primary endpoint: Device safety and functionality [347].NANOTE: All trial information accessed via ClinicalTrials.gov database. Other undescribed cohort sizes are not publicly available; ASO,antisense oligonucleotide; UPDRS, Unified Parkinson's Disease Rating Scale; MMSE,Mini-Mental State Examination; RQC, Resveratrol-Quercetin-Curcumin; NA, Not Applicable; STN, subthalamic nucleus; RCT, randomized controlled trial. NOTE: All trial information accessed via ClinicalTrials.gov database. Other undescribed cohort sizes are not publicly available; ASO,antisense oligonucleotide; UPDRS, Unified Parkinson's Disease Rating Scale; MMSE,Mini-Mental State Examination; RQC, Resveratrol-Quercetin-Curcumin; NA, Not Applicable; STN, subthalamic nucleus; RCT, randomized controlled trial. FDA novel drug therapy approvals for 2021-2025 A closer examination of these FDA-approved therapies underscores a critical point: none are direct FOXO modulators. Instead, they operate within the broader pathological networks where FOXO proteins are implicated, such as amyloid clearance (Aduhelm, Lecanemab) and neuroinflammation (Ponvory, Briumvi). This highlights that targeting FOXO itself represents a frontier yet to be fully breached in clinical practice. No.DrugActive IngredientApproval DateDisease1Ponvory [348]Ponesimod3/18/2021MS2Aduhelm [348]Aducanumab-avwa6/7/2021AD3Relyvrio [349]Sodium phenylbutyrate/taurursodiol9/29/2022ALS4Briumvi [349]Ublituximab-xiiy12/28/2022Relapsing forms of MS5Qalsody [350]Tofersen4/25/2023ALS6Leqembi [350]Lecanemab-irmb1/6/2023AD7Aqneursa [351]Levacetylleucine9/24/2024Niemann-Pick type C8Miplyffa [351]Arimoclomol9/20/2024Niemann-Pick type C9Kisunla [351]Donanemab-azbt7/2/2024ADKey observation: All approved therapies target downstream effectors or parallel pathways rather than direct FOXO modulation, indicating both the therapeutic potential and the translational challenge of direct FOXO targeting. Key observation: All approved therapies target downstream effectors or parallel pathways rather than direct FOXO modulation, indicating both the therapeutic potential and the translational challenge of direct FOXO targeting. NIH funded programs NO.DiseasesInterventionsPhasesStudy typeKey Clinical InformationDateNCT06099886PDLithium aspartate [337]1Phase I safety trialPrimary endpoint: Safety and tolerability of lithium aspartate2023/10/12-2025/4/30NCT05318040ADCMS121 [352]1Randomized, double-blind, placebo-controlledPrimary endpoint: Safety and tolerability; Next steps: Phase Ib (healthy elderly), Phase IIa (MCI/early AD)2022/5/1-20-22/12/17NCT04251182ADT3D-959 [353]2Randomized, double-blind, placebo-controlledPrimary endpoints: ADAS-Cog11, ADCS-CGIC; Key findings: 30 mg group showed near-significant ADAS-Cog11 improvement (P = 0.073); plasma Aβ42/40 ratio improved (P = 0.011)2021/3/1-20-23/2/17NCT05122598ADCOT [354]2Phase II trialPrimary endpoint: Safety and efficacy2021/11/15-2023/4/30NOTE: Status indicates current recruitment state as of registry query. FOXO-related mechanisms are inferred from published preclinical data on these interventions; ADAS-Cog, Alzheimer's Disease Assessment Scale-Cognitive Subscale; CMS121 and T3D-959, small molecule drug; COT, Computerized Olfactory Training. NOTE: Status indicates current recruitment state as of registry query. FOXO-related mechanisms are inferred from published preclinical data on these interventions; ADAS-Cog, Alzheimer's Disease Assessment Scale-Cognitive Subscale; CMS121 and T3D-959, small molecule drug; COT, Computerized Olfactory Training. Classic clinical trial cases NO.DiseasesInterventionsOutcomeStudy typeKey Clinical InformationCompletionNCT05603715PDPyridostigmine BromideImproving effect of pyridostigmine bromide on intestinal function [355]RCTSite: University of Vermont Medical Center; Primary endpoint: Effect on constipation and neurogenic orthostatic hypotensionDec-24NCT06705517PDMediterranean DietTo study the effects of the Mediterranean Diet (MED) on PD [356]RCTCohort size: n = 44; Duration: 6 months; Primary endpoint: MDS-UPDRS I + II score change (MCID = 6.3)Sep-26NCT06214377PDDopaminergic medicationInnovative combination of neurostimulation and dopamine medication for painful symptoms of PD [357]InterventionalPrimary endpoint: Pain symptom management; Intervention: Dopaminergic medication combined with neurostimulationApr-24NOTE: Data are retrieved from ClinicalTrials.gov (2023–2025). NA, not applicable; RQC, resveratrol–quercetin–curcumin; MCID, minimal clinically important difference. NOTE: Data are retrieved from ClinicalTrials.gov (2023–2025). NA, not applicable; RQC, resveratrol–quercetin–curcumin; MCID, minimal clinically important difference. Recent research on the clinical application of FOXO transcription factors, which play crucial roles in managing NDDs, has made notable progress but also encounters ongoing challenges. As the understanding of the role of the FOXO family in the onset of these conditions has expanded, clinical studies have shifted from traditional small-molecule therapies to novel strategies, including gene therapy and neuromodulation. Three significant patterns emerge from FOXO-related clinical research: First, improving the design of small-molecule modulators can increase their specificity. For example, TAK-242 activates the TLR4/FOXO1/SOD2 pathway (Section 6.1); a phase II trial (NCT06665165) has shown improved central delivery efficiency. Additionally, the natural flavonoid SMARTO ONE (NCT05947396, NCT05947409) enhances mitochondrial function by activating the FOXO-PGC-1α pathway, which is relevant to multiple NDDs. Second, notable progress has been made in the field of gene therapy vectors, particularly with AAV2-GDNF and AAV2-BDNF (Overview of gene therapy strategies detailed in Section 6) activate neuroprotective pathways downstream of FOXO (NCT04167540). Nevertheless, the immune responses induced by elevated doses of AAV9 and spikes in cerebrospinal fluid levels of IFN-γ highlight the need for careful management of immunogenicity risks. Third, emerging approaches for metabolic reprogramming, such as intranasal insulin (NCT04687878, NCT04251585) and insulin-sensitizing small molecules (NCT05227820), are known to stimulate the PI3K/AKT/FOXO1 pathway, thereby altering brain energy metabolism. A Phase Ib investigation combining puerarin with the mitochondrial enhancer GC-1 has been initiated (NCT06469853). Despite promising therapeutic advances reflected in increased research investment, considerable obstacles remain regarding safety and specificity. Off-target effects pose significant concerns, as exemplified by AS1842856 inducing 2.3-fold elevation in neuronal apoptosis through unintended PI3K-AKT pathway inhibition [293,324]. Drug-drug interactions present additional risks, with resveratrol's irreversible CYP450 enzyme inhibition potentially interfering with co-administered drug metabolism [323]. Systemic metabolic disruption represents a major limitation, as FOXO1 activation risks hepatic gluconeogenesis upregulation and peripheral insulin resistance [35,291]. Blood-brain barrier penetration remains scarce for most small molecules, requiring high systemic doses with attendant toxicity [141]. Cell-type specificity challenges persist, as current delivery strategies cannot selectively target neuronal versus glial FOXO isoforms, risking divergent outcomes [175,325,326]. Moving forward, balancing neuroprotective benefits against systemic toxicity demands enhanced regulatory frameworks, CNS-specific delivery vehicles, isoform-selective modulators, companion biomarkers for target engagement, and adaptive trial designs stratified by disease stage to align with the context-dependent nature of FOXO signaling [5,289]. In summary, while therapies targeting FOXO show significant potential for clinical use in NDDs, continuous improvement and practical implementation will be necessary to enhance treatment effectiveness and improve patient quality of life. To move forward, it will be crucial to combine allosteric modulation with thorough monitoring to align the neuroprotective advantages of FOXO with its systemic toxicity. This strategy seeks to enable targeted interventions tailored to various stages and timelines in the development of NDDs. Controversies and limitations Critical appraisal and controversies The FOXO field exhibits substantial functional heterogeneity that warrants critical acknowledgment. While mild stress-induced FOXO activation often promotes neuroprotection through antioxidant and autophagic pathways, severe or chronic stress may shift this balance toward pro-apoptotic outputs—a context-dependency that oversimplified dichotomous framing may obscure. In C. elegans, DAF-16/FOXO activation extends lifespan via stress resistance pathways [358], though whether this uniformly benefits neuronal health across all models requires further validation. Hepatic FOXO1 activation drives gluconeogenesis that supports systemic energy homeostasis but may exacerbate peripheral insulin resistance—a metabolic trade-off relevant to AD comorbidities [108,359]. FOXO-induced autophagy is generally beneficial for clearing protein aggregates, but in late-stage neurodegenerative disease, broader lysosomal dysfunction may limit this capacity regardless of FOXO status [360]. The SIRT1-FOXO axis shows context-dependent effects: deacetylation can enhance antioxidant responses [361], while chronic inflammatory signaling may alter functional outcomes through pathway crosstalk [277]. Cell-type-specific functions generate opposing outcomes: FOXO3 promotes Aβ clearance in astrocytes [210], FOXO1 regulates dopaminergic neuron metabolism [10,42], yet FOXO1 activation exacerbates skeletal muscle atrophy in ALS models [18]. These contradictions suggest that unidirectional "FOXO activation" or "inhibition" strategies may be inherently oversimplified. Limitations Research imbalance and isoform-specific gaps. Current investigations into the role of the FOXO protein family in NDDs reveal significant gaps in understanding. We contend that research has focused largely on the functions of FOXO1 and FOXO3, with insufficient exploration of the effects of FOXO4 on cellular aging and the unique influence of FOXO6 on synaptic metabolism [362]. This uneven emphasis has led to a notable deficiency in comprehensively understanding the interrelated network of the FOXO family. For example, while BDNF signaling can modulate FOXO1 activity through ERK-mediated phosphorylation [363], whether FOXO1 exerts inhibitory feedback on BDNF pathways—and whether this interaction is influenced by FOXO3—remains to be systematically validated in disease models. Technical challenges in dynamic monitoring. Substantial technical challenges exist in tracking the dynamic alterations of FOXO proteins. Most investigations analyzing the spatiotemporal shifts in phosphorylation and acetylation rely on endpoint detection methods, which limit the capacity to monitor real-time modifications in live cells [180,364]. While emerging live-cell imaging and single-cell approaches show promise, their application in neurodegenerative disease models remains limited. Translational obstacles and species discrepancies. Translational medicine faces considerable obstacles in disease modeling. Mechanisms identified in animal studies, such as the FOXO3-PINK1 axis in mitophagy, show context-dependent outcomes when assessed across species [12,150]. Human-induced pluripotent stem cell models may not fully recapitulate the metabolic and microenvironmental complexity of in vivo systems, potentially contributing to discrepancies in observed mitophagic responses. In our view, the threshold for therapeutic development remains high. The progress of therapeutic strategies has faced three major obstacles. First, the specificity of interventions aimed at particular subtypes is insufficient; current small-molecule modulators exhibit variable selectivity across FOXO family members [365]. Second, delivery mechanisms have inherent flaws, including variable distribution of viral vectors throughout the primate brain and potential immune responses [366]. Third, treatment guidelines often fail to adapt to disease stages; therapies offering protective advantages in initial phases, such as SIRT1 activators, could yield divergent outcomes under chronic inflammatory conditions [367,368]. Obvious limitations exist due to lack of system integration research. Within the regulatory network involving the gut-brain axis, metabolites produced by the gut microbiota may influence host epigenetic regulation [369,370], but direct links to neuronal FOXO activity in NDDs remain unverified. Similarly, while FOXO1 has been implicated in blood-brain barrier endothelial function [371,372], the specific role of FOXO4 in maintaining barrier integrity requires further elucidation. To address these gaps, future investigations should integrate human-derived disease models, develop subtype-specific molecular probes, and implement dynamic multi-omics monitoring systems. Conclusion and future directions Conclusion FOXO proteins do not function as uniform stress responders. Instead, they exhibit distinct functional architectures. FOXO1 acts as a metabolic gatekeeper, linking peripheral insulin signals to neuronal bioenergetics. FOXO3 serves as the primary oxidative stress sensor and coordinates mitochondrial quality control. Meanwhile, FOXO4 mediates p53-dependent senescence in glial compartments, and FOXO6 translates synaptic activity into localized metabolic adaptations. This functional specialization explains why pan-FOXO therapeutic strategies have yielded inconsistent outcomes—targeting must account for cell-type-specific expression patterns and disease-stage-dependent activity states. A critical insight emerging from this synthesis is the compartmentalized nature of FOXO dysfunction. In AD, FOXO1 dysregulation manifests primarily at the neurovascular interface, where pericyte loss disrupts blood-brain barrier integrity, whereas FOXO3 alterations concentrate in plaque-associated microglia and tangle-bearing neurons. PD presents a dichotomous pattern: FOXO1 protects dopaminergic terminals via α-syn transcriptional repression [237,373], while FOXO3 drives somatic degeneration through JNK-mediated apoptotic priming [132,374]. These observations suggest that therapeutic strategies must achieve cell-type-selective engagement rather than global pathway modulation. The temporal paradox of FOXO targeting represents a central translational challenge. Our analysis demonstrates that identical molecular interventions—whether SIRT1 activation [174], JNK inhibition [295], or direct FOXO1 allosteric modulation [293,294]—produce divergent outcomes depending on disease stage [177]. Early intervention prioritizes FOXO1-mediated autophagy enhancement and metabolic reprogramming [65,68], whereas advanced stages require FOXO3 nuclear export inhibition to prevent pro-apoptotic gene transactivation [25,41]. This stage dependency necessitates biomarker-guided patient stratification, potentially employing CSF acetylated FOXO3 ratios or imaging-based mitochondrial stress markers to define therapeutic windows [120,375]. This compartmentalized and stage-dependent nature of FOXO dysfunction carries important therapeutic implications. The apparent contradictions in FOXO function—lifespan extension coexisting with neurodegeneration in model organisms [376], autophagy promotion transitioning to autophagic exhaustion [179], antioxidant defense shifting to pro-apoptotic signaling [80,185]—challenge simplistic activation/inhibition strategies. Our analysis suggests that successful therapeutic targeting requires precise delineation of isoform-PTM-cell type-disease stage quadruplets, moving beyond pan-FOXO modulation toward context-specific interventions. Integrative network vulnerabilities offer alternative entry points for intervention. The FOXO-SIRT1-NF-κB axis exemplifies how metabolic state (NAD+ availability) couples to inflammatory tone through shared PTM [71,108,377]. Similarly, the FOXO-PGC-1α -mitophagy triad links bioenergetic failure to proteostatic collapse in a feed-forward loop amenable to combinatorial targeting [378]. Our identification of these network nodes—validated across AD, PD, HD, and ALS models—provides a rationale for polypharmacology approaches that single-agent strategies have failed to achieve [81,209]. Finally, this review highlights structural barriers to clinical translation that mechanism-focused research often overlooks. The blood-brain barrier restricts CNS bioavailability of most small-molecule FOXO modulators [140,141]; systemic FOXO1 activation risks hepatic gluconeogenesis and peripheral insulin resistance [35]; and cell-type-specific delivery remains technically immature despite advances in microglia-targeted nanoparticles [175,215]. Addressing these challenges requires convergence of medicinal chemistry, biomaterials engineering, and systems pharmacology—disciplines traditionally siloed from neurodegeneration research. Prospects Resolving the controversies outlined above, future mechanistic investigations must prioritize three critical challenges. Cryo-electron microscopy, alongside single-molecule tracking methods, will be employed to elucidate the spatial obstruction mechanism by which pathological proteins influence the FOXO/14-3-3 complex, while also revealing the rules of conformational reprogramming that dictate dynamic PTM in response to stress [39]. Comprehensive analyses of spatial metabolomics and single-cell multiomics will chart the spatiotemporal distribution of FOXO activity within neuronal-glial interaction networks across various brain regions, with a particular aim to clarify the transcellular synergistic mechanisms that drive metabolic reprogramming and epigenetic memory [120]. An organoid-microfluidic model will be developed to replicate gut-brain axis communication, confirming the biological pathway through which gut microbiota metabolites activate the GPR43-HDAC2-FOXO1 axis to modulate microglial polarization [147,175]. Clinical translation efforts should focus on precision intervention with tempered expectations. For targeted delivery, innovative nanocarriers must be created to facilitate spatiotemporally controlled drug release at pathological sites [175,331]. Liposomes designed to cross the blood-brain barrier can be engineered to co-deliver FOXO3 phosphomimetic peptides alongside anti-inflammatory agents, mitigating systemic toxicity while increasing cerebral drug bioavailability [123,298]. Personalized therapy driven by biomarkers necessitates the integration of cerebrospinal fluid acetylated FOXO levels, blood exosomal noncoding RNA profiles, and multimodal data characteristics to establish quantitative indicators for intervention timing [120,375]. In advanced AD, nuclear export inhibitors are favored to obstruct FOXO1-mediated pro-apoptotic effects [308], whereas in early PD, the focus shifts to activating FOXO1-dependent α-syn clearance pathways [173]. Systematic optimization of combination therapies should aim at pathological intersections. For cognitive impairment related to diabetes, pairing FOXO1 inhibitors with GLP-1 receptor agonists can address both peripheral insulin resistance and cerebral Aβ deposition [83,379]. In FTD, small molecules can be designed to stabilize TDP-43 dimer structures, thereby restoring their ability to bind 14-3-3 proteins and subsequently increase FOXO activity competitively [175,308]. These advances notwithstanding, the translational path forward requires cautious optimism. The "double-edged sword" nature of FOXO signaling—evident across all NDDs yet with transformation thresholds varying by disease—suggests that first-generation FOXO modulators may encounter efficacy limitations or safety signals demanding adaptive clinical trial designs (in Section 7). Success likely depends less on achieving maximal FOXO activation or inhibition, and more on restoring appropriate dynamic range to stress-responsive transcriptional networks. Ultimately, by utilizing humanized disease models and computational biology platforms, a decision matrix for interventions encompassing pathological stages, cell types, and target combinations can be developed, facilitating a shift in NDDs management from merely controlling symptoms to addressing root causes. Ethics approval and consent to participate Not applicable. This is a review article that does not involve human participants, animal experiments, or original clinical data. All cited studies in this review were carried out in accordance with ethical standards as reported in their original publications. Consent for publication Not applicable. This manuscript does not include personal data from any individual. All authors have agreed to the final version of the manuscript and consent to its publication. Availability of data and materials This review article synthesizes existing published literature. Data sharing is not applicable, as no separate datasets were generated or analyzed in this study. All referenced data are provided in the cited publications. AI tool application The authors hereby declare that generative artificial intelligence (AI) tools were utilized exclusively for language polishing and stylistic refinement during the preparation of this manuscript. Specifically, AI-assisted features in Grammarly Premium and Microsoft Word Editor were employed to enhance grammatical accuracy, improve sentence clarity, and optimize word choice. No AI system was used for literature search, data synthesis, mechanistic interpretation, generation of novel scientific hypotheses, or creation of figures and tables. Funding This study was funded by the Young Scientific and Technological Talent Growth Project of Guizhou Provincial Department of Education (Grant No. Qianjiaoji [2024]145), the Zunyi Municipal Science and Technology Support Program (Grant No. Zunshikehezhicheng [2025]41), and the Fourth Batch of the "12345" Future Talent Program (Future Renowned Clinicians) of Zunyi Medical University. No external funding was received for this study. CRediT authorship contribution statement Zhengxiang Lv: Data curation, Formal analysis, Software, Visualization, Writing – original draft. Xiaodong Liu: Investigation, Software, Validation. Zhiwei Zhou: Funding acquisition, Methodology. Qin Huang: Resources, Supervision. Haijun Liu: Conceptualization, Resources, Supervision. Zucai Xu: Investigation, Project administration, Resources. Ping Xu: Data curation, Formal analysis, Project administration, Writing – review & editing. Declaration of competing interest The authors confirm the absence of personal relationships, academic rivalries, intellectual commitments, or advisory/steering committee memberships that could be perceived as influencing the objectivity, critical appraisal, or interpretive framing of the reviewed literature. None of the authors serve on scientific advisory boards, editorial committees, or clinical trial oversight panels for pharmaceutical or biotechnology companies with direct interest in FOXO-targeted interventions. Acknowledgements The authors acknowledge the editorial teams of the cited journals for their contributions to the field. We also acknowledge the institutional support provided by the Affiliated Hospital of Zunyi Medical University and 302 Hospital, China Guihang Group. Footnotes All authors have reviewed this declaration, verify its completeness, and consent to its publication alongside the manuscript. Abbreviations β-Amyloid Aβ-binding Alcohol Dehydrogenase Alzheimer's disease Protein Kinase B Amyotrophic lateral sclerosis AMP-activated Protein Kinase Amyloid Precursor Protein α-synuclein β-site APP Cleaving Enzyme 1 B-cell Lymphoma 2 Brain-Derived Neurotrophic Factor Bcl-2 Interacting Mediator of Cell Death Catalase C–C Motif Chemokine Ligand 2 Chaperone-Mediated Autophagy Central Nervous System Excitatory Amino Acid Transporter 2 Experimental Autoimmune Encephalomyelitis Electron Transport Chain Fas Ligand Forkhead Box O Frontotemporal dementia Glucose Transporter Glutathione Peroxidase Glycogen Synthase Kinase-3β Huntington's disease Histone Deacetylase Heme Oxygenase-1 Insulin-like Growth Factor-1 Interleukin-1β c-Jun N-terminal Kinase Lysosomal-associated Membrane Protein 2A Microtubule-associated Protein 1 Light Chain 3 Leucine-rich Repeat Kinase 2 mutant huntingtin Manganese Superoxide Dismutase 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Multiple sclerosis Mechanistic Target of Rapamycin Myeloid differentiation primary response 88 Nuclear Factor Kappa B NLR family pyrin domain containing 3 Nuclear Respiratory Factor 1 or 2 Parkinson's disease Pyruvate Dehydrogenase Kinase 4 Peroxisome Proliferator-activated Receptor Gamma Coactivator 1α Phosphoinositide 3-Kinase Protein Phosphatase 2A p53 Upregulated Modulator of Apoptosis Reactive Oxygen Species Sirtuin 1 Superoxide Dismutase TAR DNA-binding Protein 43 Transcription Factor EB Transforming Growth Factor Beta T Helper 17 Cell Toll-like Receptor 4 Tumor Necrosis Factor Alpha Regulatory T Cell Triggering Receptor Expressed on Myeloid Cells 2 Unc-51 Like Autophagy Activating Kinase 1 Data availability No data was used for the research described in the article. References Associated Data Data Availability Statement This review article synthesizes existing published literature. Data sharing is not applicable, as no separate datasets were generated or analyzed in this study. All referenced data are provided in the cited publications. No data was used for the research described in the article.